10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended March 31, 2018
[   ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from __________ to __________

000-53089
Commission File Number
HCi Viocare
(Exact name of registrant as specified in its charter)
Nevada	30-0428006
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
Kintyre House, 209 Govan Road, Glasgow Scotland	G51 1HJ
(Address of principal executive offices)	(Zip Code)
+44 141 370 0321
(Registrant's telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  [X] No  [   ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  [X] No  [   ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer[  ]	Accelerated filer [  ]
Non-accelerated filer[  ] (Do not check if a smaller reporting company)	Smaller reporting company [X]
	Emerging growth company [X]

      If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  [  ] No  [X]

APPLICABLE ONLY TO REGISTRANTS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST 5 YEARS:

Indicate by check mark whether the issuer has filed all documents and reports required to be filed by Section 12, 13, or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

Yes  [   ] No  [   ]

APPLICABLE ONLY TO CORPORATE REGISTRANTS

Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date.

259,812,025 shares of common stock issued and outstanding as of June 14, 2018

 

HCI VIOCARE

TABLE OF CONTENTS

		Page
	PART I – Financial Information
Item 1	Financial Statements	4
Item 2	Management's Discussion and Analysis of Financial Condition and Results of Operations	5
Item 3	Quantitative and Qualitative Disclosures About Market Risk	9
Item 4	Controls and Procedures	9
	PART II – Other Information
Item 1	Legal Proceedings	10
Item 1A	Risk Factors	10
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	10
Item 3	Defaults Upon Senior Securities	10
Item 4	Mine Safety Disclosures	10
Item 5	Other Information	11
Item 6	Exhibits	11
	SIGNATURES	12

2

CAUTIONARY STATEMENT ON FORWARD-LOOKING INFORMATION

This Quarterly Report on Form 10-Q (this "Report") contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act").  These statements relate to future events or our future financial performance.  A number of important factors could cause our actual results to differ materially from those expressed in any forward-looking statements made by us in this Form 10-Q.  In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" or the negative of these terms or other comparable terminology.  These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

We cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that our objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. These forward-looking statements are found at various places throughout this Report and include information concerning possible or assumed future results of our operations, including statements about potential acquisition or merger targets; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future acquisitions, future cash needs, future operations, business plans and future financial results, and any other statements that are not historical facts.

These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by these forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

CERTAIN TERMS USED IN THIS REPORT

When this report uses the words "we," "us," "our," and the "Company," they refer to HCi Viocare and its consolidated subsidiaries, and "SEC" refers to the Securities and Exchange Commission.
 

3

PART I -- FINANCIAL INFORMATION.

ITEM 1.  FINANCIAL STATEMENTS

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.  In the opinion of management, all adjustments considered necessary for a fair presentation have been included.  All such adjustments are of a normal recurring nature.  Operating results for the three-month period ended March 31, 2018, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2018.  For further information, refer to the audited financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 as filed with the Securities and Exchange Commission on May 17, 2018.

	Page
Consolidated Balance Sheets (Unaudited)	F-1
Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	F-2
Consolidated Statements of Cash Flows (Unaudited)	F-3
Notes to Consolidated Financial Statements (Unaudited)	F-4 to F-24

4

HCi Viocare

CONSOLIDATED BALANCE SHEETS

	March 31, 2018			December 31, 2017
	(unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	234,380		352,498
Accounts receivable		63,497		27,557
Other receivable		68,510		59,827
Inventory		4,572		4,395
Prepaid expenses		52,942		50,525
Total Current Assets		423,901		494,802
Property, plant and equipment, net		141,197		155,029
Total Assets	$	565,098		649,831
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable, advances and accrued expenses	$	530,488		582,781
Accounts payable and accrued expenses-related party		2,711		508,853
Convertible debt, related parties		721,564		-
Income tax payable		80,000		80,000
Advances from a related party		-		341,355
Notes payable, third parties		49,287		47,921
Total Current Liabilities		1,384,050		1,560,910
Total Liabilities		1,384,050		1,560,910
Commitments and Contingencies		-
Stockholders' Equity (Deficit):
Preferred stock, par value $0.0001, 5,000,000 shares authorized; none issued and outstanding as of March 31, 2018 and December 31, 2017		-		-
Common stock, par value $0.0001, 700,000,000 shares authorized; 256,033,852 shares issued and outstanding as of March 31, 2018 and 238,385,684 shares issued and outstanding as of December 31, 2017		25,603		23,838
Additional paid-in capital		34,633,814		33,819,056
Retained Deficit		(35,430,148	)	(34,736,633	)
Accumulated other comprehensive income (loss)		(48,221	)	(17,340	)
Stockholders' equity (deficit)		(818,952	)	(911,079	)
Total Liabilities and Stockholders' Equity (Deficit)	$	565,098		649,831

See Notes to Unaudited Consolidated Financial Statements

F-1

HCi Viocare

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

	For the Three Months ended
	March 31,
	2018			2017
Sales	$	131,780		$	86,440
Cost of goods sold		39,503			47,557
Gross Profit		92,277			38,883
Operating Expenses
Depreciation		19,455			20,908
Office rent		28,586			18,704
Office expenses		63,412			40,208
Consultancy Fees		537,225			357,772
Professional fees		19,436			239,139
Research and development		83,328			78,066
Travel and entertainment		35,561			19,285
Total Operating Expenses		787,003			774,082
Income (Loss) from Operations		(694,726	)		(735,199	)
Other Income (Expenses)
Gain (Loss) on foreign currency transaction		1,825			(910	)
Interest Expenses due to third party		(614	)		(1,536	)
Total Other Income (Expenses)		1,211			(2,446	)
Income (Loss) before Provision for Income Tax		(693,515	)		(737,645	)
Provision for Income Tax		-			-
Net Income (Loss)	$	(693,515	)	$	(737,645	)
Basic and fully diluted loss per share	$	(0.00	)	$	(0.00	)
Weighted average shares outstanding		246,048,657			192,943,733
Comprehensive Income (Loss) :
Net loss	$	(693,515	)	$	(737,645	)
Effect of foreign currency translation		(30,881	)		(14,296	)
Comprehensive Loss	$	(724,396	)	$	(751,941	)

See Notes to Unaudited Consolidated Financial Statements

F-2

HCi Viocare

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Three Months Ended
	March 31,
	2018			2017
Operating Activities
Net loss	$	(693,515	)	$	(737,645	)
Adjustments to reconcile net loss to net cash used by operating activities:
Stock option expense		184,643			122,543
Shares issued for stock award		272,500			388,900
Depreciation		19,455			20,908
Changes in operating assets and liabilities:
Decrease (Increase) in accounts receivable		(34,143	)		(9,835	)
Decrease (Increase) in prepaid expense		(3,879	)		1,201
Decrease (Increase) in other receivable		(881	)		(1,066	)
Decrease (Increase) in inventory		-			522
Increase (Decrease) in accounts payable and accrued expenses		(53,412	)		34,319
Increase (Decrease) in accounts payable and accrued expenses, related party		(102,149	)		62,192
Net cash used by operating activities		(411,381	)		(117,961	)
Investing Activities
Net cash (used) by investing activities		-			-
Financing Activities
Advances and Loans from related parties		64,603			61,365
Repayments, advances and loans from related party		(122,427	)		(41,959	)
Loans from third parties		-			103,818
Proceeds from private placement		359,381			-
Net cash provided by financing activities		301,557			123,224
Increase (decrease) in cash		(109,824	)		5,263
Cash at beginning of period		352,498			2,492
Effects of exchange rates on cash		(8,294	)		(1,324	)
Cash at end of period	$	234,380		$	6,431
Supplemental Disclosures of Cash Flow Information:
Cash paid during the year for:
Interest	$	-		$	-
Income taxes	$	-		$	-
Supplemental Non-Cash Activities
Reclassification of related party accounts payable and advances to convertible debt, related parties	$	721,564		$	-

See Notes to Unaudited Consolidated Financial Statements

F-3

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 1 - ORGANIZATION AND BUSINESS BACKGROUND

HCi Viocare ("VICA" or the "Company") was incorporated on March 26, 2007 under the laws of the State of Nevada. The Company has selected December 31 as its fiscal year end.

While the Company has generated revenues from a segment of its planned principal operations, we are not yet able to meet operational overheads and are not yet profitable. We are considered an emerging growth enterprise. The Company was originally formed to sell medical devices with an emphasis on portable medical devices designed for home treatments with the initial focus in the northern regions of China.  The Company's intent was to seek strategic relationships with medical device manufacturers both in China and North America with the aim to be their sales and distribution agent in Northern China and to assist Chinese medical device manufacturers on the development of the North American market.

On September 10, 2013, the controlling shareholder of the Company sold his controlling interest in the shares of the Company and there was a change in the Board of Directors of the Company, effecting a change in control of the Company. The business of the Company remains in the field of medical devices and other opportunities related to their uses. We are currently engaged in the technology development and licensing of bioengineering innovations for the health, sports and wellness sectors, and operate a prosthetic and orthotic (P&O) total rehabilitation clinic in Glasgow, Scotland.

On January 15, 2014, the Company incorporated two wholly-owned subsidiaries in Scotland, U.K., HCi Viocare Technologies Limited and HCi Viocare Clinics UK Limited. The Company intends to operate in Scotland under these two subsidiaries, one of which will undertake the development and marketing of technologies and the other which is a P&O clinic, which will serve as the center of reference and training for the Company's further clinics.

On February 12, 2014, through our wholly owned subsidiary, HCi Viocare Technologies Limited, the Company acquired an interest in a patented technology known as "Socket-Fit". SocketFit is a system that will help overcome technical and resource hurdles endemic to the prosthetic sector. The system has been designed with the aim of offering optimally fitted prosthetic sockets that will reduce the number of prostheses made for patients, resulting in a reduced number of visits by the patient to the prosthetic, and also assisting in the rehabilitation of amputees.  Socket-Fit is a digital system for assessing an amputee's residual limb and for the production of truly functional and comfortable prosthetic sockets. The technology takes account of the external and internal geometry of the amputee's stump, the biomechanical properties of each individual soft tissue layer and the boundary and loading conditions of a complete prosthesis to generate a virtual 3D model of the residual limb making it possible to produce an accurate, functional and comfortable prosthetic socket. By minimizing the time and cost of socket production and reducing the number of faulty sockets there will be a reduction in costs incurred by health services and insurance companies worldwide as well as benefits to the amputee. The Company intends to undertake and fund, through its U.K. subsidiary, a project to improve the nature of the data used in socket modeling software with a view to creating a system that will enable prosthetists to build a socket that evenly distributes weight, provides enhanced comfort, and can be marketed and used across the industry for improved socket creation.

On February 19, 2014, the Company filed a Certificate of Amendment with the Secretary of State of Nevada to change the name of the Company to HCi Viocare effective March 21, 2014.  Effective March 21, 2014, in accordance with approval from FINRA, we changed our name from China Northern Medical Device, Inc. to HCi Viocare. Concurrently we commenced trading on the Over-the-Counter Bulletin Board under the symbol "VICA".

On April 16, 2014, through our wholly owned subsidiary HCi Viocare Technologies Limited, we acquired all rights and interest in and to the background Intellectual Property Rights ("IPR") for a developing technology known as "Smart Insole".  The Smart Insole system is believed to be a state-of-the-art, pressure and shear (friction)-sensing insole that can wirelessly communicate with connected devices.  The insole has a number of applications, including the mitigation of diabetic foot complications, such as ulceration, infection and amputation, in clinical gait analysis and in sports, as a wearable device to help athletes optimize their performance and prevent injury. The sensing system is very low cost, compared to traditional pressure sensing technologies, in our opinion making such applications affordable to the consumer for the first time.

F-4

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 1 - ORGANIZATION AND BUSINESS BACKGROUND (continued)

On June 9, 2014, the Company, through our wholly owned subsidiary, HCi Viocare Clinics, acquired W D Spence Prosthetics Limited (the "Clinic"). The Clinic is located in Glasgow, Scotland, and is a fully operational prosthetics and orthotics clinic. The acquisition of the Clinic is the first step to the Company's and HCi Viocare Clinics' intention to develop the first chain of prosthetics and orthotics (P&O) and diabetic foot rehabilitation clinics in the European market, covering Southern Europe, the Middle East and North Africa.

On March 31, 2015, the Company's wholly owned subsidiary HCi Viocare Clinics and its subsidiary W D Spence Prosthetics Limited completed a merger with the resulting combined entity having the name HCi Viocare Clinics UK Limited.

On July 8, 2015, the Company incorporated HCi Viocare Clinics (Hellas) S A in order to carry out operations for the planning and development of a P&O clinic in Athens, Greece. On August 2, 2017 the Company commenced the dissolution and liquidation of this corporation.  As at the date of this report, the dissolution has not yet been concluded.

Note 2 - GOING CONCERN

The Company incurred net losses of $693,515 and $737,645 for the three months ended March 31, 2018 and 2017, respectively and has a retained deficit of $35,430,148. In addition, the Company had a working capital deficiency of $960,149 and a stockholders' deficit of $818,952 at March 31, 2018. These factors raise substantial doubt about the Company's ability to continue as a going concern. 

There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company's existing stockholders.

The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

The Company has relied heavily for its financing needs up until the close of fiscal 2017 on its Chief Executive Officer and President as more fully disclosed in Note 10.

Note 3 - CONTROL BY PRINCIPAL STOCKHOLDER/OFFICER

Up until March 30, 2018 our Chief Executive Officer owned beneficially and, in the aggregate, the majority of the voting power of the Company.  On March 22, 2018 and March 30, 2018 respectively, Sotirios Leontaritis, the President, Chief Executive Officer and a Director of the Company, entered into a Share Purchase Agreement (the "SPA") and an amendment thereto (the "Addendum"), (collectively herein referred to herein as the "Agreement") with Maschari Ltd. ("Maschari"), a Company incorporated in Cyprus, pursuant to which Mr. Leontaritis sold 122,710,562 of his restricted common shares to Maschari. The shares sold by Mr. Leontaritis represent approximately 49.1% of the Company's total outstanding shares of common stock. Mr. Leontaritis continues to hold 20,000,000 shares of the Company's common stock representing approximately 8% of the issued and outstanding shares.  As a result of the aforementioned transaction, Maschari has the ability to control the approval of most corporate actions, including increasing the authorized capital stock and the dissolution, merger or sale of the Company's assets, as may be presented at Shareholder meetings from time to time.

F-5

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principals of Consolidation

The consolidated financial statements include the accounts of HCi Viocare and its wholly-owned subsidiaries, HCi Viocare Technologies Limited, HCi Viocare Clinics UK Limited and HCi Viocare Clinics (Hellas) S.A. On August 2, 2017 the Company commenced the dissolution and liquidation of HCi Viocare Clinics (Hellas) S.A. All significant intercompany balances and transactions have been eliminated.

Basis of Presentation

The interim unaudited financial information referred to above has been prepared and presented in conformity with accounting principles generally accepted in the United States applicable to interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The interim financial information has been prepared on a condensed basis, such that certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission. These interim financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.

This report on Form 10-Q should be read in conjunction with the Company's financial statements and notes thereto included in the Company's Form 10-K for the fiscal year ended December 31, 2017 filed on May 17, 2018. Results of the three ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ended December 31, 2018 and any other future periods.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results when ultimately realized could differ from these estimates.

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less.

Fair Value of Financial Instruments

The carrying value of financial instruments including cash and cash equivalents, receivables, prepaid expenses, accounts payable and accrued expenses, approximates their fair value due to the relatively short-term nature of these instruments.

F-6

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Foreign Currencies

Items included in the consolidated financial statements of each of the Company and its subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the 'functional currency').  The Company's reporting currency is the U.S. dollar.  The functional currency of subsidiaries based in the UK is pound sterling and the functional currency of the Company's subsidiary based in the Greece is the Euro. All transactions initiated in Pounds and Euro are translated into U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830-30, "Translation of Financial Statements," as follows:

i) assets and liabilities are translated at the closing rate at the date of the balance sheet, or

     1USD=0.81158EUR, 1USD=0.71239GBP (March 31, 2018), and;

1USD=0.8347EUR, 1USD=0.74108GBP (December 31, 2017);

ii) income and expenses are translated at average exchange rates for three months ended March 31, or

         1USD=0.8137EUR, 1USD=0.7189GBP (March 31, 2018), and;

1USD=0.93136EUR, 1USD=0.80731GBP (March 31, 2017);

iii)  all resulting exchange differences are recognized as other comprehensive income, a separate component of equity.

Adjustments arising from such translations are included in accumulated other comprehensive income (loss) in stockholders' equity.  

Revenue Recognition

Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectibility of the fee is reasonably assured.

The Company recognizes revenue when the earnings process is complete and persuasive evidence of an arrangement exists. This generally occurs for revenue recorded in our P&O Clinics division when prosthetic products are fitted to customers, both title and the risks and rewards of ownership are transferred or services have been rendered and accepted, the selling price is fixed or determinable, and collectibility is reasonably assured.  Revenue is recognized upon issuance of an invoice and completion of each concluded stage of work performed on a prosthetic product.  The Company recognizes revenue from its technology licensing fees and/or product development fees upon conclusion of services provided under contract.

There was no impact on the Company's financial statements as a result of adopting Topic 606 for the three months ended March 31, 2018 and 2017, or the fiscal year ended December 31, 2017.

F-7

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Inventory

Inventories, which consist principally of raw materials and parts, are stated at the lower of cost or market. Cost is determined using the first-in, first-out method and are adjusted to actual cost quarterly based on a physical count. Net realizable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. Work-in-process inventory consists of materials, labor and a predetermined fixed rate of overhead which is valued based on established standards for the stage of completion of each custom order. We do not carry finished goods on hand. Material, labor and overhead costs are determined at the individual clinic level. Presently we only maintain very limited parts and raw materials inventory.

Warranty

We do not record warranty liabilities at the time of sale for the estimated costs that may be incurred under the terms of the applicable limited warranty as all component parts are covered by our respective industry suppliers.

Advertising Costs

The Company expenses advertising costs as incurred or the first time the advertising takes place, whichever is earlier, in accordance with ASC 720-35. Advertising costs were immaterial for the three months ended March 31, 2018 and 2017, respectively.

Research and Development Costs

The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, "Research and Development". Research and development costs were $83,328 and $78,066 for the three months ended March 31, 2018 and 2017, respectively.

Related parties

For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.

Stock-based compensation

For stock-based compensation, the Company follows the guidance codified in the Compensation – Stock Compensation Topic of FASB ASC ("ASC 718"). The Company determines the value of stock issued at the date of grant. It also determines at the date of grant, the value of stock at fair market value or the value of services rendered (based on contract or otherwise) whichever is more readily determinable.

Income Taxes

The Company accounts for income taxes in accordance with FASB ASC 740, "Income Taxes", which requires the asset and liability approach for financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

F-8

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Income Taxes (continued)

The Company has a retained deficit from operations. Because there is no certainty that we will realize taxable income in the future, the Company did not record any deferred tax benefit as a result of these losses and recorded a valuation allowance offsetting the entire potential tax benefit.

Income tax years for 2014 through 2016 have been remitted timely and remain open to examination by the taxing authorities. The tax return for fiscal 2017 has not yet been filed. The Company has been assessed late filing penalties of $10,000 per year, as well as accrued interest thereon, for each of the late filed returns for the periods from inception to December 31, 2012. Prior to a change in control at the close of fiscal 2013, prior management had not timely filed their annual tax returns.  We have estimated and accrued penalties of $80,000 as taxes payable in our financial statements. The Company has retained a tax professional to assist in reaching a settlement with the IRS.

Basic and Diluted Loss per Share

The Company reports earnings per share in accordance with FASB ASC 260, "Earnings Per Share." FASB ASC 260 requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company had potentially dilutive securities outstanding (convertible debt and liabilities) for the period ended March 31, 2018 and December 31, 2017, respectively, however, since the Company reflected a net loss in the three months ended March 31, 2018 and 2017, the effect of considering any common stock equivalents, if outstanding, would have been anti-dilutive. A separate computation of diluted earnings (loss) per share is not presented. 

	March 31, 2018		December 31, 2017
Convertible debt at $0.03 per share		24,052,133		-
Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options		500,000		500,000
Common stock issuable upon exercise of stock options		38,000,000		28,000,000
Total		62,552,133		28,500,000

Comprehensive Income

FASB ASC 220, "Comprehensive Income", establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income, as defined, includes all changes in equity during a period, exclusive of shareholder transactions. Accordingly, comprehensive income (loss) may include certain changes in shareholders' equity (deficit) that are excluded from net income (loss).

Segment Reporting

FASB ASC 820 "Segments Reporting" establishes standards for reporting information about operating segments on a basis consistent with the Company's internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. Our proposed business segments are expected to span more than one geographical area. Specifically, the Company intends to operate prosthetic and orthotic rehabilitation clinics with various European based locations, as well as a corporate development and technology center which will undertake ongoing research and marketing activities.

F-9

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Fair Value of Measurements

Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2: Input other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company.

Level 3: Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability.

An asset or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities.

Recent Issued Accounting Pronouncements

There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company's operations, financial position or cash flows.

Note 5 - PREPAID EXPENSES

Prepaid expenses consist of the following:  

	March 31, 2018		December 31, 2017
Office lease, including security deposits	$	41,134	$	39,582
Travel advances and other expenses		11,808		10,943
Total prepaid expense	$	52,942	$	50,525

F-10

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 6 - PROPERTY AND EQUIPMENT

Property and improvements consisted of the following as of March 31, 2018 and December 31, 2017:

	March 31, 2018			December 31, 2017
Cost
Leasehold improvements	$	211,628		$	203,990
Furniture and fixture		33,967			32,781
Computers and equipment		35,406			33,144
Vehicle		61,608			59,902
Machine and plant		9,577			9,206
Lab equipment		35,497			34,123
		387,683			373,146
Less: accumulated depreciation and impairment		(246,486	)		(218,117	)
	$	141,197		$	155,029

Leasehold improvements are amortized over the term of the lease: three to ten years.

Furniture is depreciated over three to five years and computer and equipment is depreciated over three years.

Vehicles are depreciated over five years.

Machine equipment and lab equipment are depreciated over 4 years.

Depreciation expense amounted to $19,455 and $20,908 for the three months ended March 31, 2018 and 2017, respectively.

 Note 7 - OFFICE LEASE

Office in Greece

On February 3, 2014, the Company leased office space in Paleo Faliro, Greece on a three-year lease, commencing on March 1, 2014 and ending on February 28, 2017. The monthly rental fee is $1,900 (EUR € 1,554) including applicable taxes in the first year. Thereafter, for every further lease year and for the whole duration of the lease agreement, as well as in case of compulsory statutory extension or extension by tacit agreement, the monthly rent shall be annually adjusted by a percentage equal to the Consumer Price Index of the adjustment month with respect to the respective month of the year before (simple annual rate of change), as this is calculated by the Hellenic Statistical Authority (ELSTAT), plus two (2) percentage points (+2%).

Under the term of the lease agreement, the Company paid a total of $25,010 (EUR €18, 540) including $4,047 (EUR €3,000) for a deposit and $20,963 (EUR €15,540) for ten months' rental fee upon executing the agreement. As of March 31, 2018, $3,697 (EUR €3,000) is shown as deposits in the prepaid account.  The lease has been renewed effective June 13, 2017 for a term of 3 years terminating on February 28, 2020 at a rate of $1,960 (EUR€1,592) plus a fee of 3.6%  

F-11

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

 Note 7 - OFFICE LEASE (continued)

Clinic in Greece

On December 29, 2014, the Company leased office space at Peania Region of Attica in Greece on a ten-year lease, commencing on January 1, 2015 and ending on October 5, 2024. The monthly rental fee is $6,996 (EUR €6,233) plus applicable taxes and the monthly operating cost estimate is $1,120 (EUR €997).

Under the term of the lease agreement, the Company paid a total of $13,991 (EUR €12,465) as deposits in the prepaid account. 

On October 9, 2015, the terms of the lease were amended to include the following provisions:

-  Effective September 1, 2015, the monthly rental fee shall be reduced to $3,500 (EUR €3,116) for a period of 12 months ending August 31, 2016.

-  In the event that the Lessee commences leasehold improvements prior to August 31, 2016, it shall inform the Lessor respectively and pay retroactively the remaining balance of the total amount of monthly rental in full from the period commencing September 1, 2015, as if they have not been reduced;

-  In the event that the Company does not proceed with leasehold improvements in the 12-month period, the lease agreement will terminate and the Lessor with retain the deposit.

-  The Lessor until such time as the leasehold improvements commence, may at any time and without indemnity terminate the lease agreement with a 30-day prior written notice to the Lessee.

As of December 31, 2016, the Company and the Lessor concluded the Termination of Lease Agreement dated August 1, 2016, and the Lessor waived all maintenance charges and utility charges for fiscal 2016. The following table is the summary of balance owing to Lessor as at March 31, 2018 and December 31, 2017:

	March 31, 2018			December 31, 2017
Amount owed for maintenance charges		$	16,700		$	16,238
Amount owed for utility charges			17,287			16,807
		$	33,987		$	33,045

Lease in UK

On March 2, 2015, the Company entered into a lease agreement for a modern, stand-alone 5,300 square foot facility in Glasgow, Scotland with an entry date of March 1, 2015. The building will host the Company's first Viocare center, a full-service Prosthetic and Orthotic ("P&O") practice with a superior standard of personalized care. The renovations to the clinic were completed in June, and the facility was opened on August 1, 2015 with an official ribbon cutting on 25 September 2015. During the first year from the date of entry, the lease fees are USD$28,000 (GBP £20,000) per annum (exclusive of VAT). On the second anniversary of the date of entry, the lease will increase to USD$56,000 (GBP £40,000) per annum (exclusive of VAT). In the third anniversary of the date of entry, the lease will be USD$56,000 (GBP £40,000) per annum (exclusive of VAT). In the fourth anniversary of the date of entry, the lease will decrease to USD$42,000 (GBP £30,000) per annum (exclusive of VAT). In the fifth anniversary of the date of entry, the lease will be USD$56,000 (GBP £40,000) per annum (exclusive of VAT).

F-12

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 7 - OFFICE LEASE (continued)

Lease in UK (continued)

Under the term of the lease agreement, the Company paid a total of $28,075 (GBP £20,000) as security deposits which amount is included on the Company's balance sheet in prepaid expenses.  

Location	March 31, 2018		December 31, 2017
Greece	$	3,697	$	3,594
UK		37,437		35,988
	$	41,134	$	39,582

As of March 31, 2018, the approximate future aggregate minimum lease payments in respect of our current obligations were as follows:  

Location	Greece		United Kingdom
2018		17,200		33,340
2019		23,000		53,810
2020		3,800		9,360
	$	44,000	$	96,510

Note 8 -   LOANS

On January 5, 2017, HCi Viocare Clinics Hellas S.A., the Company's subsidiary, entered into a loan agreement with a third party to borrow a total of EUR 40,000 (US$49,287) with an annual interest rate of 5%, payable within one year from the date of the agreement. As at March 31, 2018 and December 31, 2017 a total of $52,325 and $50,276, respectively, including accrued interest to date, remained due and payable in respect of this loan. Interest expenses of $614 were accrued in the three months ended March 31, 2018. The loan was not repaid in January 2018 and is currently in default.

Note 9 -   COMMITMENTS

(1) Consulting Agreement with Dr. Christos Kapatos

On April 16, 2014, the Company entered into a Consulting Agreement with Christos Kapatos whereby he will provide his services as Chief Technical Officer for the Company and the Company's wholly-owned subsidiaries.  The contract has a term of one year, renewable for such further term as may be mutually agreed between the parties. In the case that a research and development project is initiated and completed during the term of the agreement, Kapatos shall receive one million four hundred thousand (1,400,000) shares of the Company's common stock for each research project completed with a valuation less than twenty million dollars ($20,000,000 USD), three million five hundred thousand (3,500,000) shares of the Company's common stock for each research project completed with a valuation equal or greater than twenty million US dollars ($20,000,000 USD). Details of compensation under the terms of the consulting agreement are included in Note 10(ii).

F-13

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 9 -   COMMITMENTS (continued)  

(2) Consulting Agreement with JAMB

Effective July 10, 2017, the Company entered into a business consulting agreement (the "Consulting Agreement") with JAMB Group LLC. ("Consultant") for services to commence July 15, 2017 and to continue for a period of twelve (12) months thereafter. Under the terms of the Agreement, the Consultant shall provide consulting services to the Company for the development and expansion of its business, including the introduction to specific Targets for the purposes of financing transactions or other business relationship. The Consultant is entitled to compensation for the provision of services in the form of 500,000 shares of the common stock which were issued upon execution of the Consulting Agreement, as well as certain other fees and consideration.  

500,000 shares have been valued at $79,950, the fair market value of $0.1599 per share, on issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017.

(3) Consulting Agreement with Mr. Stefanos Batzakis

On September 1, 2017, the Company entered into a one-year consulting agreement (the "Agreement") with Mr Stefanos Batzakis. As per terms of said Agreement Batzakis will provide services to the Company as IT Solutions Manager, for a term of one (1) year and receive compensation in the form of stock, namely five hundred thousand (500,000) common shares, which were issued upon signing of this Agreement.

500,000 shares have been valued at $40,000, the fair market value of $0.08 per share on issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017

(4) Consulting Agreement with Dr. Ioannis Doupis

On October 9, 2017, the Company appointed Dr. Ioannis Doupis, to the Advisory Board of the Company originally formed on April 15, 2014 and Concurrently entered into an advisory board agreement. Compensation shall be the grant of a total of 500,000 shares of the Company's common stock valued at the fair market price on the date of grant of $0.07 per share. The advisory board appointment is for a term of one year.

500,000 shares have been valued at $35,000, the fair market value of $0.07 per share on issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017

(5) Consulting Agreement with Ms. Paraskevi Pilarinou

On December 12, 2017, the Company entered into a consulting agreement (the "Agreement") with an Ms. Paraskevi Pilarinou (the "Consultant").  Under the terms and conditions of the Agreement the Consultant shall be employed in the position of Financial Controller of the Company. The Agreement has a three-year term starting on January 2, 2018 and ending on January 1, 2021 and the Consultant shall be remunerated with a monthly fee of EUR2,000 (IUSD$2,460) and was issued 2,000,000 shares of the Company's common stock. The 2,000,000 shares were issued as compensation as of the date of the agreement and were valued at $0.05 per share or $100,000, the fair market value on the date of issuance in the year ended December 31, 2017.

F-14

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 9 -   COMMITMENTS (continued)  

(6) Consulting Agreement with Charalampos Sgardelis

On January 2, 2017, the Company entered into a one-year consulting agreement (the "Agreement") with Mr. Charalampos Sgardelis ("Sgardelis"). Under the terms of the Agreement, Sgardelis provides services to the Company as Business Development Manager, for a term of one (1) year and receives compensation of Two Thousand Euros (2,000 €) per month.

On February 26, 2018 the Company approved a three (3) year extension to the Agreement (the "Addendum") between the Company and Sgardelis.  Under the terms and conditions of the Addendum, Sgardelis is entitled to receive compensation of Three Thousand Euros (3,000 €) per month and shall be awarded five million (5,000,000) common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $0.049 per share for total consideration of $245,000.

(7) Advisory Agreement with Ravi Vaidyanathan

On March 27, 2018, the Company entered into a one-year advisory agreement (the "Agreement") with an Mr. Ravi Vaidyanathan (the "Advisor"). Under the terms and conditions of the Agreement, the Advisor is appointed to the Company's Scientific Advisory Board and is entitled to remuneration for the provision of services in the form of 500,000 shares of the common stock to be issued upon signing of the Agreement. Further, the Advisor shall be granted additional 250,000 shares of the common stock to be issued after a time-period of six (6) months from the signing of the Agreement.  The Advisor shall serve on the Scientific Advisory Board in the position of Biomechatronics and Human Augmentation Advisor. The Company or the Advisor may terminate the agreement upon 30 days written notice.  The issued shares were valued at fair market value on the date of issuance or $0.055 per share for total consideration of $27,500.

Note 10 -   RELATED PARTY TRANSACTIONS

The following table provides details of the Company's related party transactions during the three months ended March 31, 2018 and 2017

(a) Services provided from related parties:

	Three Months ended March 31,
	2018		2017
Consulting fees from CEO and President (i)	$	38,867	$	30,000
Consulting fees from a Director (ii)		15,361		10,655
Professional fees from Director (iii)		3,687		3,196
Consulting fees for VP (iv)		12,903		6,393
Stock options granted to CEO and President (i)		122,543		122,543
Stock options granted to Director (ii)		45,300		-
Stock options granted to VP (iv)		16,800		-
Stock award granted to Director (iii)		-		172,000
Stock-based compensation (VP) (iv)		-		187,200
	$	255,461	$	409,444

F-15

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 10 -   RELATED PARTY TRANSACTIONS (cont'd)

(i)	On September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016.   Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract.  In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR$10,000 per month.  Further, Mr. Leontaritis is entitled to acquire at his discretion 3,000,000 shares of the common stock at a price of $0.30 per share for a term of five (5) years.  The Company recognized stock-based compensation expense allocated to consulting fees of $122,543 during the three months ended March 31, 2018 and 2017. The unrecognized amount of $1,838,151 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2019, Mr. Leontaritis is entitled to total minimum payments of EUR$210,000 (US$258,080).
(ii)	On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$49,290 (€40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company Euros €40,000 for services rendered in each fiscal year respectively. On December 12, 2017, the Company approved the issuance of 18,500,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant.  The 18,500,000 shares have been valued at $925,000, or $0.05 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$61,610) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 25,000,000 shares of the common stock at a price of $US0.05 for a term of six years. The Company recognized stock-based compensation expense allocated to consulting fees of $45,300 during the three months ended March 31, 2018. The unrecognized amount of $1,030,200 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2023, Dr. Kapatos is entitled to total minimum payments of EUR287,500 (US$353,324).
(iii)	On September 10, 2013, the Board of Directors of the Company elected Nikolaos Kardaras as Secretary and a director of the Company. During each of fiscal 2017 and fiscal 2016, Mr. Kardaras invoiced the Company EUR12,000 for services rendered in his capacity as a director which amount totaled US$13,500 and $13,300 respectively. On March 3, 2017, the Company approved the issuance of 1,000,000 common shares for the services provided by Mr. Nikolaos Kardaras in the form of a stock award which vested as of the date of grant. 1,000,000 shares have been valued at $172,000, the fair market value of $0.172 per share on issue date, which amount has been expensed as stock based compensation.

F-16

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 10 -   RELATED PARTY TRANSACTIONS (continued)

(a) Services provided from related parties:(cont'd)

(iv) On September 1, 2015, the Board of Directors of the Company approved a consulting agreement with Sergios Katsaros and appointed Mr. Katsaros Vice President. Under the terms of the consulting agreement, Mr. Katsaros will work directly with the Company's President and CEO in order to create and implement the Company's strategic plan and assist in securing additional financing to meet the needs of the Company's business plan and corporate objectives.  The initial term of the contract is six months and Mr. Katsaros will receive compensation of USD$2,460 (€2,000) per month. On March 1, 2016, the Company approved a one-year extension to the consulting agreement and the Company approved the grant of a stock award of 300,000 common shares as compensation for the services provided by Vice President, Sergios Katsaros.  The award vests in three equal instalments of 100,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. During fiscal 2016 a total of $169,000 in respect of 200,000 vested shares was recorded as stock based compensation. On March 1, 2017, the final instalment of 100,000 shares were issued in accordance with the terms of the award valued at $17,200, the fair market value on grant date, which amount has been expensed as stock-based compensation in 2017.   On March 17, 2017, the Company approved the issuance of a further 1,000,000 common shares for the services provided by Mr. Katsaros, in the form of a stock award which vested as of the date of grant. 1,000,000 shares have been valued at $170,000, the fair market value of $0.17 per share on grant date, which amount has been expensed as stock-based compensation.   On December 12, 2017 the Company approved a three-year extension to the consulting agreement between the Company and Mr. Katsaros effective as of January 2, 2018.  The revision to the Agreement has a term of three years, being effective as of January 2, 2018, and ending on January 1, 2021, renewable for such further term as may be mutually agreed between the parties. Mr. Katsaros shall be remunerated with a monthly stipend of EUR3,500 (US$4,310), and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Mr. Katsaros shall also be entitled to acquire at his discretion 10,000,000 shares of the common stock at a price of $US0.05 for a term of five years commencing January 2, 2018.   The Company recognized stock-based compensation expense allocated to consulting fees of $16,800 during the three months ended March 31, 2018. The unrecognized amount of $320,300 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2021, Mr. Katsaros is entitled to total minimum payments of EUR115,500 (US$141,944).

(b) Accounts payable and accrued liabilities from related parties:

	March 31,			December 31,
	2018			2017
CEO and President (i)	$	306,423		$	413,010
Director (ii)		116,229			95,843
Director (iii)		863			-
VP (iv)		1,848			-
Reclassification to Convertible Debt, Related parties		(422,652	)
	$	2,711		$	508,853

(c) Advances from related parties:

	March 31,			December 31,
	2018			2017
CEO and President (i)	$	283,191		$	287,073
Director (ii)		15,721			54,282
Reclassification to Convertible Debt, Related Parties		(298,912	)
	$	-		$	341,355

(d) Convertible Debt, related parties:

On February 15, 2018, the Company and certain shareholders holding in excess of 5% of the Company's common stock and concurrently holding a position on the Company's Board, or acting in the capacity of any officer of the Company or its subsidiaries, agreed that repayment against pre-existing debt payable by the Company on the agreement date shall be  suspended until such time as  the Company concludes a full profitable year of operations. Further the parties agreed that any such pre-existing debt or portion thereof shall be convertible at any time into restricted shares of the Company's common stock at a price equal or greater to $0.03 per share. On the date of the agreement the fair market value of the Company's common stock as traded on OTCMarkets was $0.0403 per share. The Company accounted for this transaction by applying ASC 470-20-35.  As the convertible debt has no stated redemption date, the Company will recognize the discount as interest expense on the earliest conversion date.  

The Company has reclassified all debts payable as of February 15, 2018 to our CEO and CTO from advances and accounts payable, related party, to convertible debt, related party.  At March 31, 2018 a total of $721,564 in debt   was convertible into 24,052,133 shares of restricted common stock.

F-17

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 11 -   CAPITAL STOCK

The Articles of Incorporation authorize the Company to issue 5,000,000 shares of preferred stock with a par value of $0.0001, and 700,000,000 shares of common stock with a par value of $0.0001.  No shares of preferred stock have been issued, however, the Company has granted 25,000 fully vested stock options for the purchase of 25,000 shares of Series A Preferred Stock of the Company at a price of $0.04 per share for a period of five (5) years from the date of vesting. (ref: Note 13 below)  

Share issuances during the three months ended March 31, 2018

During the three months ended March 31, 2018, 12,148,168 shares of common stock were issued in respect of various private placements for total cash proceeds of $359,381.

During the three months ended March 31, 2018, the Company issued 5,500,000 shares to employees, board members and consultants valued at $272,500, for services rendered.  The Company valued these issuances based on the closing price of the Company's stock as reflected on the OTC Markets on the respective dates of issuance.

Designation of Series A Preferred Stock

On January 13, 2014, the Company filed a Certificate of Designation with the Secretary of State of the State of Nevada.   The Certificate of Designation sets forth the rights, preferences and privileges of a class of the Company's preferred stock.  Such class shall be designated as the "Series A Preferred Stock" and the number of shares constituting such series shall be 5,000,000 shares.  The holders of Series A Preferred Stock will be entitled to a preference over all of the shares of the Company's common stock.  Holders of Series A Preferred Stock shall have 50 votes per share of Series A Preferred Stock held by them and shall be entitled to notice of any stockholders' meeting and to vote as a single class upon any matter submitted to the stockholders for a vote.  Each share of Series A Preferred Stock is convertible into 20 shares of our common stock at any time at the holder's option.  Shares of Series A Preferred Stock shall not be entitled to any dividends.  The preferred stock shall be entitled to a preference over all of the shares of common stock of the Company with respect to the distribution of assets in the event of the liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs.

Note 12 - STOCK OPTIONS

A total of 25,000 stock options granted during April and June of fiscal 2014 entitling each holder the right to purchase a total of 5,000 shares of Series A Preferred Stock of the Company at a price of $0.04 per share for a period of five (5) years remain unexercised and outstanding as at March 31, 2018.  The Series A Preferred shares are convertible on the basis of 20 shares of common stock for each one share held and have voting rights of 50 votes per share of Series A Preferred stock held at any meetings of the stockholders.

F-18

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 12 - STOCK OPTIONS (continued)

On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019. Further, Mr. Leontaritis is entitled to acquire at his discretion 3,000,000 shares of the common stock at a price of $0.30 per share for a term of five (5) years.

On December 12, 2017, Dr. Christos Kapatos, director, was issued a stock option as part of an extension to his employment contract whereunder, at his discretion, he may to acquire 25,000,000 shares of the common stock at a price of $US0.05 for a term of six years.

Mr. Katsaros shall also be entitled to acquire at his discretion 10,000,000 shares of the common stock at a price of $US0.05 for a term of five years commencing January 2, 2018.

The Company accounts for share-based payments pursuant to ASC 718, "Stock Compensation" and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company's stock price and expected dividends.

Stock compensation expense for stock options is recognized over the vesting period of the award.

The Company recognized stock-based compensation expense allocated to consulting fees of $184,643 and $122,543 during the three months ended March 31, 2018 and 2017, respectively. The unrecognized amount of $3,188,651 will be expensed in future periods.

The following table summarizes information concerning stock options outstanding as of March 31, 2018, and December 31, 2017:

Series A Preferred Stock:

	March 31, 2018				December 31, 2017
	Series A Preferred stock		Weighted Average Exercise Price $		Series A Preferred stock		Weighted Average Exercise Price $
Outstanding at beginning of the year		25,000		0.04		25,000		0.04
Granted		-		-		-		-
Exercised		-		-		-		-
Expired or canceled		-		-		-		-
Outstanding at the period		25,000		0.04		25,000		0.04

The aforementioned options have an average remaining life of 1.07 years. 

F-19

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 12 - STOCK OPTIONS (continued)

Common stock:

	March 31, 2018				December 31, 2017
	Common stock		Weighted Average Exercise Price $		Common stock		Weighted Average Exercise Price $
Outstanding at beginning of the year		28,000,000		0.076		-		-
Granted		10,000,000		0.05		28,000,000		0.076
Exercised		-		-		-		-
Expired or canceled		-		-		-		-
Outstanding at the period		38,000,000		0.070		28,000,000		0.076

The aforementioned options have an average remaining life of 5.55 years. 

Valuation Assumptions

The Company accounts for share-based payments pursuant to ASC 718, "Stock Compensation" and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company's stock price and expected dividends.

Stock compensation expense for stock options is recognized over the vesting period of the award.

The following table presents the range of the weighted average fair value of options granted and the related assumptions used in the Black-Scholes model for stock option grants:

Series A Preferred Stock:  

	Options Granted September 30, 2014
Fair value of options granted	1.40 ~ 2.00
Assumptions used:
Expected life (years) (a)		1.00
Risk free interest rate (b)		0.11%
Volatility (c)	117.09 ~ 119.83 %
Dividend yield (d)		0.00

Common stock:

	Options Granted date
Fair value of options granted	0.038 ~ 0.925
Assumptions used:
Expected life (years) (a)	5 ~ 6
Risk free interest rate (b)	1.93% ~ 2.25%
Volatility (c)	175.40% ~ 254.86%
Dividend yield (d)	0.00

F-20

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 12 - STOCK OPTIONS (continued)

Valuation Assumptions (continued)

The Company utilizes the Black-Scholes option pricing model to determine the fair value of each option award. Expected volatilities are based on the historical volatility of the Company's common stock over a period consistent with that of the expected term of the options. The expected term of the options are estimated based on factors such as vesting periods, contractual expiration dates and historical exercise behavior. The risk-free rates for periods within the contractual life of the options are based on the yields of U.S. Treasury instruments with terms comparable to the estimated option terms. The dividend yield rate is not considered in the model, as the Company has not established a dividend policy for the stock.

Note 13– PROVISION FOR INCOME TAXES:

The Company's operations in Greece have no tax free income threshold and are subject to taxation at a rate of 29% applied to all net income earned after $1 Euro.  Further, after its first year of profitable operations, the Company is required to remit estimated income taxes prorated monthly based on the prior year's calculated income taxes payable.

The Company's operations in the United Kingdom are subject to Corporation Tax at a single taxation rate of 20% calculated on net income.  The Company's operations are subject to certain relief from taxation with respect to R&D credit claims and may be subject to "Patent Box" relief which provides for a lower rate of income tax payable on all licensing income generated from the corporate owned patents.  There are numerous criteria required to be met to qualify for such relief.

The Company has experienced losses since inception. As a result, it has incurred no U.S. Federal income tax. The Internal Revenue Code allows net operating losses (NOL's) to be carried forward and applied against future profits for a period of twenty years. The Greece Tax Code permits such carryforwards for a period of five years. The United Kingdom Tax Code permits such carryforwards indefinitely. The total of these NOL's at March 31, 2018 was $2,891,200 in the U.S., $1,391,200 in Greece and $301,680 in the U.K.  and as at December 31, 2017 was $2,888,000 in the U.S., $1,343,400 in Greece and $307,080 in the U.K.

On December 22, 2017, the 2017 Tax Cuts and Jobs Act (the Tax Act) was enacted into law including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. While the Company has revenue we have no foreign earnings and therefore, we do not anticipate the impact of a transition tax. We have remeasured our U.S. deferred tax assets at a statutory income tax rate of 21% during fiscal 2017. Since the Tax Act was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12 months, we consider the accounting of any transition tax, deferred tax re-measurements, and other items to be incomplete due to the forthcoming guidance and our ongoing analysis of final year-end data and tax positions. We expect to complete our analysis within the measurement period in accordance with SAB 118, and no later than fiscal year end December 31, 2018.

F-21

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 13 – PROVISION FOR INCOME TAXES: (continued)

The provision for income taxes in US consists of the following:

	Three months ended March 31,
	2018			2017
Current operations	$	99,200		$	204,457
Timing differences, Stock based compensation		(96,000	)		(132,226	)
Less, Change in valuation allowance		(3,200	)		(72,231	)
Net refundable amount	$	-		$	-

 The provision for income taxes in Greece consists of the following:

	Three months ended March 31,
	2018			2017
Current operations	$	47,800			$	15,380
Less, Change in valuation allowance		(47,800	)			(15,380	)
Net refundable amount	$	-			$	-

The provision for income taxes in UK consists of the following:

	Three months ended March 31,
	2018			2017
Current operations	$	11,200		$	16,654
Research and development		(16,600	)		(13,113	)
Less, Change in valuation allowance		5,400			(3,541
Net refundable amount	$	-		$	-

The cumulative tax effect at the expected rates in the U.S., in Greece and in the U.K. for significant items comprising our net deferred tax amounts reported in US Dollars as of March 31, 2018 and December 31, 2017 are as follows:

	March 31, 2018									December 31, 2017
	US Expected rate 21%			Greece Expected rate 29%			UK Expected rate 20%			US Expected rate 21%			Greece Expected rate 29%			UK Expected rate 20%
Deferred tax asset attributable to:
Net operating loss carryover		2,891,200			1,391,200			301,680			4,654,100			1,343,400			307,080
Change in effective tax rates		-			-			-			(1,766,100	)		-			-
Less, Valuation allowance		(2,891,200	)		(1,391,200	)		(301,680	)		(2,888,000	)		(1,343,400	)		(307,080	)
Net deferred tax asset		-			-			-			-			-

F-22

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 13 – PROVISION FOR INCOME TAXES: (continued)

The Company has no tax position at December 31, 2017 and December 31, 2016 for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. As a result of a re-assessment of certain late tax filings completed for the fiscal years ended 2007 through 2012 the IRS has assessed late filing penalties of approximately $80,000, which we have recognized and accrued in our balance sheets at December 31, 2017. The Company had no accruals for interest and penalties at December 31, 2016. The Company is aggressively negotiating with the IRS to have a portion or all of these penalties waived in a future period. The Company's utilization of any net operating loss carry forward may be unlikely as a result of its intended activities.

The Company recognized deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carryforwards. The Company will establish a valuation allowance to reflect the likelihood of realization of deferred tax assets.

Note 14 - SEGMENT REPORTING

The Company's operations are classified into two reportable segments that provide different products or services. Separate management of each segment is required because each business unit is subject to different marketing, operations, and growth and technology development strategies.

The Clinics segment derives its revenue from provision of services at our P&O Clinic located in Glasgow, Scotland. The Technology segment derives its income from the licensing of its proprietary technologies and ultimately recurring royalty income as well as technology access fees. Presently we are only deriving income from our UK-based operations.  We expect this to be the case until such time as we are able to expand our chain of P&O Clinics.

There are no inter-segment sales however, the Company's two primary operating segments do share costs on certain operational overhead including facility rent and staff salaries.

Three months ended March 31, 2018:

	Clinics (UK)		Technology (UK)			All Other (Greece)			Total
Revenue	$	126,890	$	4,890		$	-		$	131,780
Depreciation & amortization	$	2,357	$	11,247		$	5,851		$	19,455
Net (Loss) from operations	$	20,469	$	(76,551	)	$	(637,433	)	$	(693,515	)
Interest expenses	$	-	$	-		$	(614	)	$	(614	)
Assets	$	277,638	$	146,554		$	140,906		$	565,098
Expenditure on long-lived assets	$	-	$	-		$	-		$	-

Three months ended March 31, 2017:

	Clinics (UK)			Technology (UK)			All Other (Greece)			Total
Revenue	$	83,884		$	2,556		$	-		$	86,440
Depreciation & amortization	$	2,231		$	10,771		$	7,906		$	20,908
Loss from operations	$	(23,319	)	$	(58,947	)	$	(652,933	)	$	(735,199	)
Interest expenses	$	(1.040	)	$	-		$	(496	)	$	(1,536	)
Assets	$	60,154		$	158,104		$	95,480		$	313,738
Expenditure on long-lived assets	$	-		$	-		$	-		$	-

F-23

HCi Viocare

Notes to Unaudited Consolidated Financial Statements

For the Three Months Ended March 31, 2018

Note 16 - SUBSEQUENT EVENTS

On May 3, 2018 the Company awarded 100,000 shares of the Company's restricted common stock to Mr. Nikolaos Gemelos as consideration for his services rendered as Consultant. The shares were valued at fair market value on the date of issuance or US$0.067 per share for total consideration of $6,700.

On May 23, 2018 the Company approved an amendment to the term of the scientific advisory agreement with Dr. Christos Kapatos, board member CTO and member of the Scientific Advisory Board, originally entered into on April 15, 2014 in order to extend the term to April 15, 2019.

On May 24, 2018 the Company incorporated a wholly owned subsidiary for purposes of completing a merger and name change from HCi Viocare to Rafina Innovations, Inc. Concurrently the Company's Board of Directors approved a reverse share split on the basis 20 for 1.  Upon effect of the reverse split, our authorized capital will decrease from 700,000,000 shares of common stock to 35,000,000 shares of common stock and correspondingly, our current issued and outstanding shares of common stock will decrease from 259,762,025 to approximately 12,988,101 shares of common stock, all with a par value of $0.0001.  Our preferred shares will remain unchanged.  The Company has filed the agreement and plan of merger as well as the articles of amendment with the State of Nevada and the Financial Industry Regulatory Authority ("FINRA").  

The Company's trading symbol will remain unchanged and is OTCMarkets:VICA.  The Company's CUSIP will change to 75063R106.

The Company expects the aforementioned transactions to become effective on July 3, 2018. We will announce the completion of FINRA review and the effectiveness of these changes on the market by filing a Current Report on Form 8-K.

On May 31, 2018, the Company entered into a Debt Settlement and Subscription Agreement with the President of the Company, Mr. Sotirios Leontaritis. At March 31, 2018, the Company was indebted to Leontaritis in the amount of US$589,614 in respect to certain unpaid salary, advances for operational shortfalls and certain unsettled expense reimbursements. Leontaritis has agreed to accept 3,333,333 shares of the Company's common stock at a price of US$0.03 per share to settle US$100,000 of the debt pursuant to the terms and conditions set forth in the agreement.

On June 7, 2018, the Company entered into a six-month services agreement with Mr. Georgios Dritsoulas. As per terms of said Agreement, Mr. Dritsoulas will provide services to the Company as Consultant for the development and expansion of the Company's business for a term of six (6) months. Mr. Dritsoulas received compensation of fifty thousand (50,000) restricted common shares as compensation for the services provided.

On June 11, 2018, the Company entered into a Private Placement Subscription Agreement with Mr. Constantinos Zertalis, Director and beneficial owner of our controlling shareholder, Maschari Ltd. ("Maschari"). Under the terms of the Agreement Mr. Zertalis subscribed directly for a total of 294,840 shares of the Company's common stock at a purchase price of US$0.05 per share for total cash proceeds of US$14,724. The shares are subject to applicable resale restrictions.  Prior to the aforementioned subscription agreement, Mr. Zertalis owned 122,710,562 shares of the common stock of HCi Viocare indirectly through Maschari, and 986,815 shares of the Company's common stock directly.

The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there are no additional subsequent events to disclose.

F-24

Item 2. Management's Discussion and Analysis of Financial Conditions and Results of Operations

The following discussion and analysis of the results of operations and financial condition of HCi Viocare for the three month period ended March 31, 2018 shall be read in conjunction with the financial statements and notes. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results of the timing of events could differ materially from those projected in these forward-looking statements as a result of a number of factors, including those set forth under the Risk Factors, Special Note Regarding Forward-Looking Statements and Business sections in our Form 10-K as filed with the Securities and Exchange Commission on May 17, 2018. We use words such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "believe," "intend," "may," "will," "should," "could," and similar expressions to identify forward-looking statements.

BUSINESS OVERVIEW

We were incorporated in the State of Nevada on March 26, 2007 as a company intending to sell medical devices in the northern regions of China. Our intent was to seek strategic relationships with medical device manufacturers both in China and North America with the aim to be their sales and distribution agent in northern China. We also intended to assist Chinese medical device manufacturers on the development of the North American market. The Company did not find suitable relationships with which to progress its business until it undertook a change in management in September 2013. With the change in management, the Company determined that it would initially concentrate on the development and marketing of medical and athletic devices in Europe where management had identified several opportunities for entry into the market for prosthetics and orthotics, as well as sensor based technology, and we commenced commercialization of our various products. We currently have various patents, and patents in progress, for the development of certain healthcare innovations including various athletic applications relative to our Flexisense^TM sensor technology.  In addition, during fiscal 2015, we opened our first Prosthetics and Orthotics total rehabilitation clinic in Glasgow, Scotland.  During fiscal 2016, our flagship P&O clinic in Scotland completed its first full year of operations after relocation to a larger state of the art facility which allowed for a substantive increase in our period over period revenues.  Presently our revenue stream is derived primarily from the Company's flagship P&O clinic with some initial commercial income from prospective licensing partners for applications of our developed technology. Our comparative gross revenue period over period for the three months ended March 31, 2018 reflected an increase of over 200%.

As we continue to implement our growth strategy, our complementary business model of 1) creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and 2) developing a wide portfolio of proprietary hardware solutions with first in line the Flexisense^TM sensor system, aiming to empower the user by providing on demand information in the fields of Digital Health, Prosthetics, Orthotics, Diabetes, Assistive Devices, Sports and Wellbeing, and licensing to established industry participants. HCi Viocare is listed on the OTC Markets in the USA (OTCMarkets: VICA), has its executive office in Athens, Greece and its R&D center in Glasgow, UK.

We have two wholly-owned Scottish subsidiaries: HCi Viocare Technologies Limited and HCi Viocare Clinics UK Limited, and one wholly owned Greek subsidiary, HCi Viocare Clinics (Hellas) S A.  Our Greek subsidiary is currently being liquidated and dissolved.

The Company's technologies and R&D portfolio presently consists of:

•   Filing of 3 patents in the UK: pressure sensor system; pressure & shear; pressure & positioning (Dec 2014) (all of which patents were abandoned upon the filing of a new International (PCT) patent application in December 2015 which covers over 140 countries around the world, and includes further advances made to the sensor systems, and a wider range of applications in products that touch people's everyday lives; Filing of 4 national patents for the flexisense technology, following the progression of the PCT patent: Chinese Patent Application United States Patent Application Canadian Patent Application European Patent Application  

•   2 further patents drafted and pending filing during fiscal 2018, with a further 4 patent applications currently in draft form;

•   In excess of 12 prototypes: including 4 different types of  pressure & shear insoles and diabetic walkers; smart cushions, force platessmart mattresses, and tires, with several of these prototypes in the commercialization stage;  

•   1 proof of concept device: robotic surgical assistive device;

•   High level diagrams or complex documentation and software for other innovations in the portfolio.  

•  Various customized prototypes in testing and development with commercial partners.

5

Key business developments and material events in the most recently completely quarter ended March 31, 2018 and to date
 

On January 31, 2018 the Company announced that it will commence development of its own proprietary Blockchain based system for handling sensitive client records in its flagship Prosthetics and Orthotics clinic in Scotland.  Furthermore, the team plans to develop a proprietary Blockchain based system for handling and storing the data produced from the medical applications of its Flexisense^TM technology.

On February 15, 2018, the Company entered into a Term Sheet with Mr. Georgios Thrapsaniotis and Mrs. Stella Thrapsanioti, his spouse ("Stella"), pursuant to which Mr. and Mrs. Thrapsaniotis will purchase certain securities of the Company at a fixed price of US$0.03 per share.  Upon execution of the Term Sheet, one or multiple Private Placement Subscription Agreements are agreed to be entered into during  the immediately following 10 days for total proceeds of USD $360,000 in respect of the issuance of a total of  12,000,000 shares of the restricted common stock of the Company.  As at the date of the Term Sheet, Mr. and Mrs. Thrapsaniotis collectively owned 18,049,898 restricted shares of the Company's common stock.

The Term Sheet also provides that Mr. Thrapsaniotis, or his designee, shall be entitled to hold the position of Treasurer of the Company, provided that Mr. and Mrs. Thrapsaniotis hold in excess of 5% of the Company's issued and outstanding common stock collectively, until the conclusion of a full profitable year irrespective of the number of shareholdings held individually or collectively by them at the relevant time. Furthermore, it is agreed by and between the shareholders of the Company who hold as of the date of the Term Sheet in excess of 5% of the Company's common stock, and concurrently hold a position on the Company's Board, or act in the capacity of any officer of the Company or its subsidiaries, that he/she shall not be entitled to receive any repayment against pre-existing debt owed by the Company, as of February 15, 2018, as it is recorded in the Company's financial records, except as otherwise agreed in writing.

Effective February 15, 2018, Mr. Sotirios Leontaritis resigned from his position as the Treasurer of the Company. Concurrently, the Board of Directors appointed Mr. Georgios Thrapsaniotis ("Thrapsaniotis") as a member of the Board of Directors of the Company. Mr. Thrapsaniotis was also appointed Treasurer in accordance with the provisions of a Term Sheet more fully described above.

On February 16, 2018, Thrapsaniotis subscribed for a total of 12,000,000 shares of the Company's restricted common stock at US$0.03 per share for total cash proceeds of $360,000.  Concurrently, Thrapsaniotis and Stella became affiliates of the Company, holding jointly a total of 30,049,898 shares of the Company's common stock or 11.99% percent of the total issued and outstanding share capital.

On March 27, 2018, the Company entered into a one-year advisory agreement with Mr. Ravi Vaidyanathan (the "Advisor"). Under the terms and conditions of the Agreement, the Advisor is appointed to the Company's Scientific Advisory Board and shall serve in the position of Biomechatronics and Human Augmentation Advisor.

On March 22, 2018 and March 30, 2018 respectively, Sotirios Leontaritis, the President, Chief Executive Officer and a Director of the Company, entered into a Share Purchase Agreement (the "SPA") and an amendment thereto (the "Addendum"), (collectively herein referred to herein as the "Agreement") with Maschari Ltd. ("Maschari"), a Company incorporated in Cyprus, pursuant to which Mr. Leontaritis sold 122,710,562 of his restricted common shares to Maschari. Mr. Leontaritis received in exchange a Promissory Note dated March 30, 2018, to reflect the terms of the Agreement, in the principal amount of US$7,362,633 or US$0.06 per share, which note shall come due on March 29, 2021. The parties agreed that in the event Maschari defaults on the obligation to pay the Purchase Price according to the terms of the Agreement and the Promissory Note, Maschari will surrender the shares and shall return ownership of said shares to Mr. Leontaritis.  Further, under the terms of the Agreement, the common shares are to be registered in the name of Maschari, however, until such time as the Promissory Note is paid in full, or the parties agree by written addendum thereto to the release of shares on a pro-rata basis in such amounts as may equal installment payments received, the shares shall remain encumbered. Further, in the event of any reverse split, forward split, cancellation or class conversion, as may occur in the normal course, which impacts the Company's common shares, it is agreed by the parties that such replacement shares, regardless of class and number, will continue to remain in escrow and may not be sold until paid in full and/or the parties have agreed to their release on a pro-rata basis for consideration received.

The shares sold by Mr. Leontaritis represent approximately 49.1% of the Company's total outstanding shares of common stock. Mr. Leontaritis continues to hold 20,000,000 shares of the Company's common stock representing approximately 8% of the issued and outstanding shares.

On May 23, 2018 the Company approved an amendment to the term of the scientific advisory agreement with Dr. Christos Kapatos, board member CTO and member of the Scientific Advisory Board, originally entered into on April 15, 2014 in order to extend the term to April 15, 2019.

On May 31, 2018, the Company entered into a Debt Settlement and Subscription Agreement with the President of the Company, Mr. Sotirios Leontaritis. At March 31, 2018, the Company was indebted to Leontaritis in the amount of US$589,614 in respect to certain unpaid salary, advances for operational shortfalls and certain unsettled expense reimbursements. Leontaritis has agreed to accept 3,333,333 shares of the Company's common stock at a price of US$0.03 per share to settle US$100,000 of the debt pursuant to the terms and conditions set forth in the agreement.

Additional information on the Company's activities, technologies and management team can be found at the Company's website: http://www.hciviocare.com

Other than as set out herein, we have not been involved in any bankruptcy, receivership or similar proceedings, nor have we been a party to any material reclassification, merger, consolidation or purchase or sale of a significant amount of assets not in the ordinary course of our business.

6

RESULTS OF OPERATIONS

Comparison of the Three Months Ended March 31, 2018 and 2017

Revenue, Cost of Revenue, and Gross Profit - We have incurred losses since inception. We generated $131,780 in revenues from operations and $39,503 in costs of goods sold for the three months ended March 31, 2018, compared to $86,440 in revenue and $47,557 in costs of goods sold for the three month period ended March 31, 2017.   The current quarter increase in revenue is due to customer growth in our P&O clinic.  This increase quarter over quarter from fiscal 2017 to fiscal 2018 is despite the fact that the GBP declined substantially in value period over period, which greatly impacts our US dollar reporting results as the majority of our income is earned in GBP. The decrease to costs of goods sold period over period is due improved pricing from our suppliers for prosthetic devices and associated products.  In addition period over period we experienced an increase in consultation and repair services for which there are no associated costs of goods as these services are provided by salaried employees.

Operating Expenses – Operating expenses totaled $787,003 in the three months ended March 31, 2018 and were slightly increased as compared to operating expenses of $774,082 in the prior three month comparative period.   While professional fees decreased dramatically period over period from $239,139 in fiscal 2017 to only $19,436 in the current three month period ended March 31, 2018, Consulting fees increased substantially from $357,772 (2017) to $537,225 in 2018.  In both cases the change in reported expenses relates to stock based compensation.  During fiscal 2017 the Company recorded stock based compensation of $172,000 as professional fees relative to certain stock awards granted to a director for professional services rendered, with no similar expenditure in the current fiscal quarter ended March 31, 2018.  During the current three months ended March 31, 2018 consulting fees include an increase to consulting fees as a result of increased stock based compensation to consultants and officers period over period.  Office rent, research and development and travel expenses also increased in the three months ended March 31, 2018 as compared to results from the same three month period in 2017.

Loss from Operations – During the three-month periods ended March 31, 2018 and 2017 we recorded losses from operations of $694,726 and $735,199 respectively.

Other expenses - During the three months ended March 31, 2018, the Company recorded a gain from other expense of $1,211 as compared to a loss from other expense in the three months ended March 31, 2017 of $2,446.  The gain in the current period is the result of the impact of the effects of foreign currency translation and a reduction to interest expenses in the current three month period.

Net Loss - During the comparative three month periods ended March 31, 2018 and 2017, the Company recorded a net loss of $693,515 and $737,645 respectively.

CAPITAL RESOURCES AND LIQUIDITY

At March 31, 2018, we had $234,380 cash on hand, $63,497 in accounts receivables, $68,510 in other receivables, $4,572 in inventory, and prepaid expenses of $52,942 for total current assets of $423,901.  Further we had current liabilities of $533,199 in accounts payable and accrued expenses (including amounts due to related parties), $721,564 as convertible debt, related parties, $80,000 in income taxes payable and $49,287 in short term notes from third parties.   We had a working capital deficit of $960,149 as at March 31, 2018. While the Company's prosthetics and orthotics clinic in Glasgow has greatly increased its patient through-put year over year, sales were not sufficient to cover our consolidated operational expenses.  We commenced generating revenue from commercial evaluation of our available technologies in fiscal 2016, however we had limited revenue in this segment in the three months ended March 31, 2018, as we continue to work towards a larger commercial licensing contract.  Presently we rely on our advances from our President and director, as well as private placements from qualified investors, and our Board members, to fund our general operating expenses.   We secured loans and advances from related parties during the three months ended March 31, 2018 of $64,603 and made repayments towards related party advances of $122,427 in the period. The Company has closed private placements in the amount of $359,381 in the three months ended March 31, 2018.  These amounts contribute to our ongoing operating expenses and obligations until such time as the Company can conclude a larger equity based financing, anticipated during the fiscal year 2018.

7

The Company expects it will need to raise a total of $5,000,000 to $15,000,000 to fund its proposed operations for the next twelve to thirty-six months, including the planned expansion of its Viocare Clinics to add up to 5 additional site locations. It intends to fund operations by a combination of related party loans, debt financing and equity placements, as well as through joint venture partnerships negotiated in our recently completed quarter. The Company is seeking equity private placements from qualified investors with which to fund operations until such time as it can secure alternate financing arrangements.  The Company is also seeking joint venture partners for its various Insole technology applications as a further means to fund ongoing commercialization efforts.

There can be no assurance that continued funding will be available on satisfactory terms.

GOING CONCERN

The Company incurred net losses of $693,515 and $737,645 for the three months ended March 31, 2018 and 2017, respectively and has a retained deficit of $35,430,148. In addition, the Company had a working capital deficiency of $960,149 and a stockholders' deficit of $818,952 at March 31, 2018. These factors raise substantial doubt about the Company's ability to continue as a going concern. 

There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company's existing stockholders.

NEED FOR ADDITIONAL FINANCING

Costs associated with being a public company are much higher than those of a private company. HCi Viocare has chosen public registration before the business has developed a predictable cash flow. There are present registration expenses and future legal and accounting expenses, future reporting requirements to the SEC, future exchange listing requirements, and future investor relations costs that must be borne by a public company but not by a private company. These costs can be a burdensome expense which could adversely affect our financial survival. The ongoing regulatory costs, reporting requirements, and management details, which must be met when registering and maintaining a public company, may make the economic viability of HCi Viocare very doubtful.  In addition, the Company requires additional financing in order to continue to execute its business plan which includes the commercialization of one or more technologies, the ongoing operation of a P&O clinic in Glasgow, the opening of several additional P&O clinics in identified European markets, as well as other strategically placed P&O clinics, as well as ongoing research and development to bring new technologies to market.

In the past we have relied on advances from our President and private placements from accredited investors to cover our operating costs. There can be no assurance that any other capital will be available if and when required from qualified investors or related parties.   Our need for capital may change dramatically if we acquire an interest in a business opportunity during that period which requires us to provide financing. Recently we have entered into a joint venture agreement with a third party for a series of P&O clinics in the Kingdom of Saudi Arabia.  While the burden of the financing rests with our joint venture partner, our revenue stream from these clinics will not commence until such time as they are in operation, at which time we will commence earning management fees. Further there can be no assurance that we will identify and conclude contracts for our various technologies which will result in profitable operation. We cannot assure that we will be successful in consummating any acquisition or contracts on favorable terms or that we will be able to profitably manage any business venture we acquire. Should we require additional capital, we may seek additional advances from officers, sell common stock or find other forms of debt financing.

CRITICAL ACCOUNTING POLICIES

Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States ("GAAP"). GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, and revenue and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

Our significant accounting policies are summarized in Note 4 of our financial statements for the three-month period ended March 31, 2018.  While all these significant accounting policies impact our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause a material effect on our consolidated results of operations, financial position or liquidity for the periods presented in this report.

8

RECENT ACCOUNTING PRONOUNCEMENTS

There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company's operations, financial position or cash flows.  During the period the Company adopted ASC 606 – Revenue from Contracts with Customers. There was no impact on the Company's financial statements as a result of adopting Topic 606 for the three months ended March 31, 2018 and 2017, or the twelve months ended December 31, 2017.

OFF BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as "special purpose entities" (SPEs).

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, under supervision and with the participation of the Company's Principal Executive Officer and Principal Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined under Exchange Act Rule 13a-15(e). Based upon this evaluation, the Principal Executive Officer and Principal Financial Officer concluded that, as of March 31, 2018, because of the material weakness in our internal control over financial reporting ("ICFR") described below, our disclosure controls and procedures were not effective.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that required information to be disclosed in our reports filed or submitted under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that required information to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

During the period covered by this report, there were no changes (including corrective actions with regard to significant deficiencies or material weaknesses) in our internal controls over financial reporting that occurred that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

9

PART II - OTHER INFORMATION

Item 1. Legal Proceedings. 

Viocare, Inc. a New Jersey corporation (the «Plaintiff») filed a complaint on October 24, 2016 in the United States District Court, District of Nevada objecting to the use of the name «viocare» by HCi Viocare, of Nevada (the «Defendant»). The Company and Viocare Inc. have agreed to terms of settlement effective October 19, 2017.  Under the terms of the settlement, among other concessions the Company has agreed to the following:

 - To remove "Viocare" from its registered name in the State of Nevada, its website and all usage in the United States of America and Canada, including any registered trademarks;

 - Continued use of the HCi Viocare and such other similar registered marks and domains outside the United States and Canada;

 - No objection to the Plaintiff's use of its mark in Europe provided Plaintiff does not use for P&O clinics, or goods and services related diabetic foot care; and,

- The Company undertook to terminate the website at http://www.hciviocare.com and assign Company's URL(s) to Plaintiff.

The Company is in the process of completing a name change in the State of Nevada in order to comply with this settlement.

We know of no other material, active or pending legal proceedings against our Company, nor of any proceedings that a governmental authority is contemplating against us.

Item 1A. Risk Factors.

Smaller reporting companies are not required to provide the information required by this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On June 7, 2018, the Company entered into a six-month services agreement with Mr. Georgios Dritsoulas. As per terms of said Agreement, Mr. Dritsoulas will provide services to the Company as Consultant for the development and expansion of the Company's business for a term of six (6) months. Mr. Dritsoulas received compensation of fifty thousand (50,000) restricted common shares as compensation for the services provided.

There were no unregistered securities to report which were sold or issued by the Company without the registration of these securities under the Securities Act of 1933 in reliance on exemptions from such registration requirements, within the period covered by this report, which have not been previously included in a Quarterly Report on Form 10-Q or a Current Report on Form 8-K.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

10

Item 5. Other Information.

(a) The Company has received two oppositions for use of the filed trade mark «Flexisense» by the Company in certain usage classes.  The first  being a USPTO Office Action and another from the company Grupo Flexi de Leon, S.A. de C.V. 

The FLEXISENSE word mark (Serial Number 86969718) and the class IC 025 in connection with footwear and shoes has been abandoned due to opposition of Grupo Flexi de Leon S.A. de C.V.

With regard to the FLEXISENSE design mark (Serial Number 86969716), we are required to submit specimens to show use in each class in the application: IC 009, IC 010 and IC 012. As our specimens are not yet available we have filed an extension of time for another six months from May 31, 2018, and we are expecting the consent of USPTO.

(b) On May 24, 2018 the Company incorporated a wholly owned subsidiary for purposes of completing a merger and name change from HCi Viocare to Rafina Innovations, Inc. Concurrently the Company's Board of Directors approved a reverse share split on the basis 20 for 1.  Upon effect of the reverse split, our authorized capital will decrease from 700,000,000 shares of common stock to 35,000,000 shares of common stock and correspondingly, our current issued and outstanding shares of common stock will decrease from 259,762,025 to approximately 12,988,101 shares of common stock, all with a par value of $0.0001.  Our preferred shares will remain unchanged.  The Company has filed the agreement and plan of merger as well as the articles of amendment with the State of Nevada and the Financial Industry Regulatory Authority ("FINRA").  

The Company's trading symbol will remain unchanged and is OTC Markets:VICA.  The Company's CUSIP will change to 75063R106.

The Company expects the aforementioned transactions to become effective on July 3, 2018. We will announce the completion of FINRA review and the effectiveness of these changes on the market by filing a Current Report on Form 8-K.

Item 6. Exhibits, Financial Statement Schedules

 

Exhibits:	Description
10.1	June 7, 2018 Services Agreement between the Company and Georgios Dritsoulas.	Filed herewith
31.1	Certification of Principal Executive Officer and Principal Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
32.1	Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith
101.CAL	XBRL Taxonomy Extension Calculation Linkbase	Filed herewith
101.DEF	XBRL Taxonomy Extension Definition Linkbase	Filed herewith
101.INS	XBRL Instance Document	Filed herewith
101.LAB	XBRL Taxonomy Extension Label Linkbase	Filed herewith
101.PRE	XBRL Taxonomy Extension Presentation Linkbase	Filed herewith
101.SCH	XBRL Taxonomy Extension Schema	Filed herewith

11

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HCi Viocare
Date:	June 20, 2018	By:	/s/ Sotirios Leontaritis
		Name:	Sotirios Leontaritis
		Title:	Chief Executive Officer and President (Principal Executive Officer) Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

12

EX-10.1

Services Agreement

This services agreement (the "Agreement") dated this 7^th day of June, 2018 by and between:

1.HCi Viocare, a company incorporated pursuant to the laws of the State of Nevada, U.S.A., having an office at Kintyre House, 209 Govan Road, Glasgow, Scotland, UK G51 1HJ, with company registration number E0214052007-4 (hereinafter referred to as "The Company") and

2.Georgios Dritsoulas, Greek citizen, residing at 16 Kefallinias St., Alimos, 17455, Greece, holder of the Greek Passport No. AP0252726 issued on 29.01.2018 by Iss. Office N.P.C. (hereinafter referred to as "Consultant").

Recitals

I. The Company is in the business of healthcare and wishes to raise funds in order to enforce its operation and expand its business (the "Project"). As per this Project, The Company wishes to identify potential investors. In view of the Project, The Company wishes to obtain services from Consultant as more particularly described herein ("Scope of Services and Manner of Performance").

II. Consultant is a professional in the business of providing such services and has agreed to provide the services under the terms and conditions set forth in this Agreement.

Now, therefore, in consideration of the faithful performance of the obligations set forth herein and other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, Consultant and The Company hereby agree as follows:

Terms

1.Scope of Services.  Consultant shall provide services to The Company for the development of the Project, pertaining the enforcement of its operation and the expansion of its business through the identification of potential qualified investors for the Company. Under this Agreement, Consultant undertakes to identify and introduce potential investors (the"Investors") to The Company. The Company does not, hereby, undertake to conclude any transaction with the introduced Investors.

2.Manner of performance.  Consultant shall provide services for The Company and shall introducethe Investors to The Company. The time, place and manner of performance of the services hereunder, including the amount of time allocated by Consultant, shall be determined at the sole discretion of Consultant.

3.Status of Consultant.  Consultant shall act as an independent consultant and not as an agent or employee of The Company and Consultant shall make no representation as an agent or employee of The Company. Consultant shall furnish and be responsible for all costs related to this Agreement which shall be related to the services provided by Consultant. Consultant shall have no authority to bind The Company or incur other obligations on behalf of The Company. Likewise, The Company shall have no authority to bind or incur obligations on behalf of Consultant.

1

4.Confidentiality Agreement.  In the event The Company discloses information to Consultant that The Company considers to be secret, proprietary or non-public it shall notify Consultant. Consultant agrees to hold said information in confidence. Proprietary information shall be used by Consultant only in connection with services rendered under this Agreement. Proprietary information shall not be deemed to include information that is in or becomes in the public domain without violation of this Agreement by The Company or is rightfully received from a third entity having no obligation to The Company and without violation of this Agreement.  In reciprocal, The Company agrees to hold confidential all trade secrets of and methods employed by Consultant in fulfillment of services rendered.

5.Indemnification.  The Company and Consultant mutuallyagree that they shall at all times abide by all of the regulations of the respective jurisdictions in which they perform their services.  The Company agrees to indemnify and hold harmless Consultant against any losses, claims, damages, liabilities and/or expenses (including any legal or other expenses reasonably incurred in investigating or defending any action or claim in respect thereof) to which Consultant may become subject to, because of the actions of The Company or its agents. Likewise, Consultant agrees to indemnify and hold harmless The Company against any losses, claims, damages, liabilities and/or expenses (including any legal or other expenses reasonably incurred in investigating or defending any action or claim in respect thereof) to which The Company may become subject to, because of the actions of Consultant or its agents.

6.Conflict of Interest.  Consultant shall be free to perform services for other persons. Consultant shall notify in writing The Company of its performance of identical or similar services for any other company that could conflict with its obligations under this Agreement.

7.Term.  The term of this Agreement shall be for a time-period of six (6) months, starting on 08.05.2018 and ending on 07.11.2018 or upon written notice by either party to the other of their intent to terminate the Agreement. Commitment shall begin upon execution, by both parties, of this Agreement. Upon mutual agreement in writing the parties may renew or extend this Agreement.

8.Compensation.Consultant shall receive compensation in the form of stock, namely fifty thousand (50,000) restricted common shares of The Company (the "Compensation Shares") to be issued upon signing of this Agreement.  The Compensation Shares shall be issued as fully paid and non-assessable and shall be subject to applicable resale restrictions. The Compensation Shares shall be considered fully earned and beneficially owned upon the execution date of this Agreement, and shall be non-refundable in every respect, even in the event of early termination of this Agreement.

9.     Securities Law.  The issuance and sale of the Compensation Shares to The Consultant will be made in reliance on an exemption from the registration requirements contained in Regulation S promulgated under the Securities Act of 1933, as amended (the "1933 Act").  The Company reserves the right to request from The Consultant any additional certificates or representations required to establish an exemption from applicable securities legislation prior to the issuance of any Compensation Shares.

The certificates representing the Compensation Shares to be issued to The Consultant will be affixed with the following legends describing such restrictions:

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE "ACT"), AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT PROVIDED BY REGULATION S PROMULGATED UNDER THE ACT. SUCH SECURITIES MAY NOT BE REOFFERED FOR SALE OR RESOLD OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S, PURSUANT TO AN EFFECTIVE REGISTRATION UNDER THE ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE ACT. HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT.

2

The Consultant represents and warrants that at the time of entry into this Agreement and on the date of the issuance of any Compensation Shares that:

· The Consultant understands and agrees none of the Compensation Shares have been or will be registered under the 1933 Act, or under any state securities or "blue sky" laws of any state of the United States, and, unless so registered, may not be offered or sold in the United States or, directly or indirectly, to U.S. Persons, as that term is defined in Regulation S under the 1933 Act ("Regulation S"), except in accordance with the provisions of Regulation S, pursuant to an effective registration statement under the 1933 Act, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act and in each case only in accordance with applicable state and foreign securities laws;

· The Consultant is not a U.S. Person (as such term is defined in Regulation S of the 1933 Act) and is not acquiring the Compensation Shares for the account or benefit of, directly or indirectly, any U.S. Person and is outside the United States when receiving and executing this Agreement;

· The Consultant understands and agrees that offers and sales of any of the Compensation Shares prior to the expiration of the period specified in Regulation S (such period hereinafter referred to as the "Distribution Compliance Period") shall only be made in compliance with the safe harbor provisions set forth in Regulation S, pursuant to the registration provisions of the 1933 Act or an exemption therefrom, and that all offers and sales after the Distribution Compliance Period shall be made only in compliance with the registration provisions of the 1933 Act or an exemption therefrom and in each case only in accordance with applicable state and federal securities laws;

· The Consultant acknowledges that it has not acquired the Compensation Shares as a result of, and will not itself engage in, any "directed selling efforts" (as defined in Regulation S under the 1933 Act) in the United States in respect of any of the Securities which would include any activities undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market in the United States for the resale of any of the Compensation Shares; provided, however, that The Consultant may sell or otherwise dispose of any of the Compensation Shares pursuant to registration of any of the Compensation Shares pursuant to the 1933 Act and any applicable securities laws or under an exemption from such registration requirements and as otherwise provided herein; and

· hedging transactions involving the Compensation Shares may not be conducted unless such transactions are in compliance with the provisions of the 1933 Act and in each case only in accordance with applicable securities laws.

10.Severability.  This Agreement may be dissolved at any time provided that a thirty (30) day prior written notice is duly serviced to the other party. In the event any part of this Agreement shall be held to be invalid by any competent court or arbitration panel, this Agreement shall be interpreted as if only that part is invalid and that the parties to this Agreement will continue to execute the rest of this Agreement to the best of their abilities unless both parties mutually consent in writing to the cancellation of this Agreement.

11.Notices. Any notice or other communication required or which may be given hereunder shall be in writing and shall be hand delivered, telegraphed, telexed, or transmitted by facsimile, or sent by certified, registered or express mail, or postage prepaid, and shall be deemed given when so delivered personally, telegraphed, telexed or sent/transmitted by facsimile, or if mailed, two (2) days after the date of mailing, addressed as follows:

If to the Company: HCi Viocare

                               Contact – Sotirios Leontaritis

                               Tel: +30 211 012 30 53-4

                               Email: info@hciviocare.com

                               2A Kolokotroni st. 17563, P. Faliro, Greece

If to Contractor: Georgios Dritsoulas

                           Tel: +30 6972 226 766

                           Email: dritsoulas.inc@gmail.com

                           16 Kefallinias st., 17455, Alimos, Greece

3

12.No modification – assignment. All terms of this Agreement are considered substantial, valid and in force. No modifications of this Agreement shall be enforceable unless said modification is in writing and signed by both Consultant and The Company. This Agreement is not assignable by either party without the prior written consent of the other.

13.       Headings. Headings are inserted for the convenience of the Parties only and are not to be considered when interpreting this Agreement.

14.       Governing law and jurisdiction. This Agreement is construed and shall be interpreted in accordance with the laws of the State of Nevada, U.S.A. The parties hereby irrevocably submit to the exclusive jurisdiction of the courts of Nevada, for any dispute arising out of this Agreement and/or its performance.

In witness hereof The Company and Consultant have caused this Agreement to be executed as below.

The Company

/s/Sotirios Leontaritis

___________________

HCi Viocare

By: Sotirios Leontaritis

Title: CEO

I hereby certify that I agree to the terms of the services agreement above and am authorized to enter into this services agreement.

Consultant

/s/Georgios Dritsoulas

________________

Consultant

By: Georgios Dritsoulas

I hereby certify that I agree to the terms of the services agreement above and am authorized to enter into this services agreement.

4

EX-31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Sotirios Leontaritis, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of HCi Viocare;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.           The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 20, 2018	By:	/s/ Sotirios Leontaritis
		Sotirios Leontaritis
		Title: President, Chief Executive Officer, Chief Financial Officer, and Director (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Sotirios Leontaritis, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Quarterly Report on Form 10-Q of HCi Viocare for the three months ended March 31, 2018 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of HCi Viocare.

Dated: June 20, 2018	/s/Sotirios Leontaritis
	Sotirios Leontaritis
	President, Chief Executive Officer, Chief Financial Officer and Director
	(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
	HCi Viocare

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to HCi Viocare and will be retained by HCi Viocare and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	Jun. 14, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	HCi Viocare
Entity Central Index Key	0001402737
Trading Symbol	VICA
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		259,812,025

XML

Consolidated Balance Sheets - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 234,380	$ 352,498
Accounts receivable	63,497	27,557
Other receivable	68,510	59,827
Inventory	4,572	4,395
Prepaid expenses	52,942	50,525
Total Current Assets	423,901	494,802
Property, plant and equipment, net	141,197	155,029
Total Assets	565,098	649,831
Current Liabilities:
Accounts payable, advances and accrued expenses	530,488	582,781
Accounts payable and accrued expenses-related party	2,711	508,853
Convertible debt, related parties	721,564
Income tax payable	80,000	80,000
Advances from a related party		341,355
Notes payable, third parties	49,287	47,921
Total Current Liabilities	1,384,050	1,560,910
Total Liabilities	1,384,050	1,560,910
Commitments and Contingencies
Stockholders' Equity (Deficit):
Preferred stock, par value $0.0001, 5,000,000 shares authorized; none issued and outstanding as of March 31, 2018 and December 31, 2017
Common stock, par value $0.0001, 700,000,000 shares authorized; 256,033,852 shares issued and outstanding as of March 31, 2018 and 238,385,684 shares issued and outstanding as of December 31, 2017	25,603	23,838
Additional paid-in capital	34,633,814	33,819,056
Retained Deficit	(35,430,148)	(34,736,633)
Accumulated other comprehensive income (loss)	(48,221)	(17,340)
Stockholders' equity (deficit)	(818,952)	(911,079)
Total Liabilities and Stockholders' Equity (Deficit)	$ 565,098	$ 649,831

XML

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	700,000,000	700,000,000
Common stock, shares issued	256,033,852	238,385,684
Common stock, shares outstanding	256,033,852	238,385,684

XML

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Sales	$ 131,780	$ 86,440
Cost of goods sold	39,503	47,557
Gross Profit	92,277	38,883
Operating Expenses
Depreciation	19,455	20,908
Office rent	28,586	18,704
Office expenses	63,412	40,208
Consultancy Fees	537,225	357,772
Professional fees	19,436	239,139
Research and development	83,328	78,066
Travel and entertainment	35,561	19,285
Total Operating Expenses	787,003	774,082
Income (Loss) from Operations	(694,726)	(735,199)
Other Income (Expenses)
Gain (Loss) on foreign currency transaction	1,825	(910)
Interest Expenses due to third party	(614)	(1,536)
Total Other Income (Expenses)	1,211	(2,446)
Income (Loss) before Provision for Income Tax	(693,515)	(737,645)
Provision for Income Tax
Net Income (Loss)	$ (693,515)	$ (737,645)
Basic and fully diluted loss per share	$ 0	$ 0
Weighted average shares outstanding	246,048,657	192,943,733
Comprehensive Income (Loss) :
Net loss	$ (693,515)	$ (737,645)
Effect of foreign currency translation	(30,881)	(14,296)
Comprehensive Loss	$ (724,396)	$ (751,941)

XML

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating Activities
Net loss	$ (693,515)	$ (737,645)
Adjustments to reconcile net loss to net cash used by operating activities:
Stock option expense	184,643	122,543
Shares issued for stock award	272,500	388,900
Depreciation	19,455	20,908
Changes in operating assets and liabilities:
Decrease (Increase) in accounts receivable	(34,143)	(9,835)
Decrease (Increase) in prepaid expense	(3,879)	1,201
Decrease (Increase) in other receivable	(881)	(1,066)
Decrease (Increase) in inventory		522
Increase (Decrease) in accounts payable and accrued expenses	(53,412)	34,319
Increase (Decrease) in accounts payable and accrued expenses, related party	(102,149)	62,192
Net cash used by operating activities	(411,381)	(117,961)
Investing Activities
Net cash (used) by investing activities
Financing Activities
Advances and Loans from related parties	64,603	61,365
Repayments, advances and loans from related party	(122,427)	(41,959)
Loans from third parties		103,818
Proceeds from private placement	359,381
Net cash provided by financing activities	301,557	123,224
Increase (decrease) in cash	(109,824)	5,263
Cash at beginning of period	352,498	2,492
Effects of exchange rates on cash	(8,294)	(1,324)
Cash at end of period	234,380	6,431
Cash paid during the year for:
Interest
Income taxes
Supplemental Non-Cash Activities
Reclassification of related party accounts payable and advances to convertible debt, related parties	$ 721,564

XML

Organization and Business Background

3 Months Ended

Mar. 31, 2018

Organization and Business Background [Abstract]

ORGANIZATION AND BUSINESS BACKGROUND

Note 1 - ORGANIZATION AND BUSINESS BACKGROUND

HCi Viocare ("VICA" or the "Company") was incorporated on March 26, 2007 under the laws of the State of Nevada. The Company has selected December 31 as its fiscal year end.

While the Company has generated revenues from a segment of its planned principal operations, we are not yet able to meet operational overheads and are not yet profitable. We are considered an emerging growth enterprise. The Company was originally formed to sell medical devices with an emphasis on portable medical devices designed for home treatments with the initial focus in the northern regions of China.  The Company's intent was to seek strategic relationships with medical device manufacturers both in China and North America with the aim to be their sales and distribution agent in Northern China and to assist Chinese medical device manufacturers on the development of the North American market.

On September 10, 2013, the controlling shareholder of the Company sold his controlling interest in the shares of the Company and there was a change in the Board of Directors of the Company, effecting a change in control of the Company. The business of the Company remains in the field of medical devices and other opportunities related to their uses. We are currently engaged in the technology development and licensing of bioengineering innovations for the health, sports and wellness sectors, and operate a prosthetic and orthotic (P&O) total rehabilitation clinic in Glasgow, Scotland.

On January 15, 2014, the Company incorporated two wholly-owned subsidiaries in Scotland, U.K., HCi Viocare Technologies Limited and HCi Viocare Clinics UK Limited. The Company intends to operate in Scotland under these two subsidiaries, one of which will undertake the development and marketing of technologies and the other which is a P&O clinic, which will serve as the center of reference and training for the Company's further clinics.

On February 12, 2014, through our wholly owned subsidiary, HCi Viocare Technologies Limited, the Company acquired an interest in a patented technology known as "Socket-Fit". SocketFit is a system that will help overcome technical and resource hurdles endemic to the prosthetic sector. The system has been designed with the aim of offering optimally fitted prosthetic sockets that will reduce the number of prostheses made for patients, resulting in a reduced number of visits by the patient to the prosthetic, and also assisting in the rehabilitation of amputees.  Socket-Fit is a digital system for assessing an amputee's residual limb and for the production of truly functional and comfortable prosthetic sockets. The technology takes account of the external and internal geometry of the amputee's stump, the biomechanical properties of each individual soft tissue layer and the boundary and loading conditions of a complete prosthesis to generate a virtual 3D model of the residual limb making it possible to produce an accurate, functional and comfortable prosthetic socket. By minimizing the time and cost of socket production and reducing the number of faulty sockets there will be a reduction in costs incurred by health services and insurance companies worldwide as well as benefits to the amputee. The Company intends to undertake and fund, through its U.K. subsidiary, a project to improve the nature of the data used in socket modeling software with a view to creating a system that will enable prosthetists to build a socket that evenly distributes weight, provides enhanced comfort, and can be marketed and used across the industry for improved socket creation.

On February 19, 2014, the Company filed a Certificate of Amendment with the Secretary of State of Nevada to change the name of the Company to HCi Viocare effective March 21, 2014.  Effective March 21, 2014, in accordance with approval from FINRA, we changed our name from China Northern Medical Device, Inc. to HCi Viocare. Concurrently we commenced trading on the Over-the-Counter Bulletin Board under the symbol "VICA".

On April 16, 2014, through our wholly owned subsidiary HCi Viocare Technologies Limited, we acquired all rights and interest in and to the background Intellectual Property Rights ("IPR") for a developing technology known as "Smart Insole".  The Smart Insole system is believed to be a state-of-the-art, pressure and shear (friction)-sensing insole that can wirelessly communicate with connected devices.  The insole has a number of applications, including the mitigation of diabetic foot complications, such as ulceration, infection and amputation, in clinical gait analysis and in sports, as a wearable device to help athletes optimize their performance and prevent injury. The sensing system is very low cost, compared to traditional pressure sensing technologies, in our opinion making such applications affordable to the consumer for the first time.

On June 9, 2014, the Company, through our wholly owned subsidiary, HCi Viocare Clinics, acquired W D Spence Prosthetics Limited (the "Clinic"). The Clinic is located in Glasgow, Scotland, and is a fully operational prosthetics and orthotics clinic. The acquisition of the Clinic is the first step to the Company's and HCi Viocare Clinics' intention to develop the first chain of prosthetics and orthotics (P&O) and diabetic foot rehabilitation clinics in the European market, covering Southern Europe, the Middle East and North Africa.

On March 31, 2015, the Company's wholly owned subsidiary HCi Viocare Clinics and its subsidiary W D Spence Prosthetics Limited completed a merger with the resulting combined entity having the name HCi Viocare Clinics UK Limited.

On July 8, 2015, the Company incorporated HCi Viocare Clinics (Hellas) S A in order to carry out operations for the planning and development of a P&O clinic in Athens, Greece. On August 2, 2017 the Company commenced the dissolution and liquidation of this corporation.  As at the date of this report, the dissolution has not yet been concluded.

XML

Going Concern

3 Months Ended

Mar. 31, 2018

Going Concern [Abstract]

GOING CONCERN

Note 2 - GOING CONCERN

The Company incurred net losses of $693,515 and $737,645 for the three months ended March 31, 2018 and 2017, respectively and has a retained deficit of $35,430,148. In addition, the Company had a working capital deficiency of $960,149 and a stockholders' deficit of $818,952 at March 31, 2018. These factors raise substantial doubt about the Company's ability to continue as a going concern. 

There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company's existing stockholders.

The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

The Company has relied heavily for its financing needs up until the close of fiscal 2017 on its Chief Executive Officer and President as more fully disclosed in Note 10.

XML

Control by Principal Stockholder/Officer

3 Months Ended

Mar. 31, 2018

Control by Principal Stockholder/Officer [Abstract]

CONTROL BY PRINCIPAL STOCKHOLDER/OFFICER

Note 3 - CONTROL BY PRINCIPAL STOCKHOLDER/OFFICER

Up until March 30, 2018 our Chief Executive Officer owned beneficially and, in the aggregate, the majority of the voting power of the Company.  On March 22, 2018 and March 30, 2018 respectively, Sotirios Leontaritis, the President, Chief Executive Officer and a Director of the Company, entered into a Share Purchase Agreement (the "SPA") and an amendment thereto (the "Addendum"), (collectively herein referred to herein as the "Agreement") with Maschari Ltd. ("Maschari"), a Company incorporated in Cyprus, pursuant to which Mr. Leontaritis sold 122,710,562 of his restricted common shares to Maschari. The shares sold by Mr. Leontaritis represent approximately 49.1% of the Company's total outstanding shares of common stock. Mr. Leontaritis continues to hold 20,000,000 shares of the Company's common stock representing approximately 8% of the issued and outstanding shares.  As a result of the aforementioned transaction, Maschari has the ability to control the approval of most corporate actions, including increasing the authorized capital stock and the dissolution, merger or sale of the Company's assets, as may be presented at Shareholder meetings from time to time.

XML

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2018

Summary of Significant Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Note 4 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principals of Consolidation

The consolidated financial statements include the accounts of HCi Viocare and its wholly-owned subsidiaries, HCi Viocare Technologies Limited, HCi Viocare Clinics UK Limited and HCi Viocare Clinics (Hellas) S.A. On August 2, 2017 the Company commenced the dissolution and liquidation of HCi Viocare Clinics (Hellas) S.A. All significant intercompany balances and transactions have been eliminated.

Basis of Presentation

The interim unaudited financial information referred to above has been prepared and presented in conformity with accounting principles generally accepted in the United States applicable to interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The interim financial information has been prepared on a condensed basis, such that certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission. These interim financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.

This report on Form 10-Q should be read in conjunction with the Company's financial statements and notes thereto included in the Company's Form 10-K for the fiscal year ended December 31, 2017 filed on May 17, 2018. Results of the three ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ended December 31, 2018 and any other future periods.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results when ultimately realized could differ from these estimates.

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less.

Fair Value of Financial Instruments

The carrying value of financial instruments including cash and cash equivalents, receivables, prepaid expenses, accounts payable and accrued expenses, approximates their fair value due to the relatively short-term nature of these instruments.

Foreign Currencies

Items included in the consolidated financial statements of each of the Company and its subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the 'functional currency').  The Company's reporting currency is the U.S. dollar.  The functional currency of subsidiaries based in the UK is pound sterling and the functional currency of the Company's subsidiary based in the Greece is the Euro. All transactions initiated in Pounds and Euro are translated into U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830-30, "Translation of Financial Statements," as follows:

i) assets and liabilities are translated at the closing rate at the date of the balance sheet, or

     1USD=0.81158EUR, 1USD=0.71239GBP (March 31, 2018), and;

1USD=0.8347EUR, 1USD=0.74108GBP (December 31, 2017);

ii) income and expenses are translated at average exchange rates for three months ended March 31, or

         1USD=0.8137EUR, 1USD=0.7189GBP (March 31, 2018), and;

1USD=0.93136EUR, 1USD=0.80731GBP (March 31, 2017);

iii)  all resulting exchange differences are recognized as other comprehensive income, a separate component of equity.

Adjustments arising from such translations are included in accumulated other comprehensive income (loss) in stockholders' equity. 

Revenue Recognition

Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectibility of the fee is reasonably assured.

The Company recognizes revenue when the earnings process is complete and persuasive evidence of an arrangement exists. This generally occurs for revenue recorded in our P&O Clinics division when prosthetic products are fitted to customers, both title and the risks and rewards of ownership are transferred or services have been rendered and accepted, the selling price is fixed or determinable, and collectibility is reasonably assured.  Revenue is recognized upon issuance of an invoice and completion of each concluded stage of work performed on a prosthetic product.  The Company recognizes revenue from its technology licensing fees and/or product development fees upon conclusion of services provided under contract.

There was no impact on the Company's financial statements as a result of adopting Topic 606 for the three months ended March 31, 2018 and 2017, or the fiscal year ended December 31, 2017.

Inventory

Inventories, which consist principally of raw materials and parts, are stated at the lower of cost or market. Cost is determined using the first-in, first-out method and are adjusted to actual cost quarterly based on a physical count. Net realizable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. Work-in-process inventory consists of materials, labor and a predetermined fixed rate of overhead which is valued based on established standards for the stage of completion of each custom order. We do not carry finished goods on hand. Material, labor and overhead costs are determined at the individual clinic level. Presently we only maintain very limited parts and raw materials inventory.

Warranty

We do not record warranty liabilities at the time of sale for the estimated costs that may be incurred under the terms of the applicable limited warranty as all component parts are covered by our respective industry suppliers.

Advertising Costs

The Company expenses advertising costs as incurred or the first time the advertising takes place, whichever is earlier, in accordance with ASC 720-35. Advertising costs were immaterial for the three months ended March 31, 2018 and 2017, respectively.

Research and Development Costs

The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, "Research and Development". Research and development costs were $83,328 and $78,066 for the three months ended March 31, 2018 and 2017, respectively.

Related parties

For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.

Stock-based compensation

For stock-based compensation, the Company follows the guidance codified in the Compensation – Stock Compensation Topic of FASB ASC ("ASC 718"). The Company determines the value of stock issued at the date of grant. It also determines at the date of grant, the value of stock at fair market value or the value of services rendered (based on contract or otherwise) whichever is more readily determinable.

Income Taxes

The Company accounts for income taxes in accordance with FASB ASC 740, "Income Taxes", which requires the asset and liability approach for financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company has a retained deficit from operations. Because there is no certainty that we will realize taxable income in the future, the Company did not record any deferred tax benefit as a result of these losses and recorded a valuation allowance offsetting the entire potential tax benefit.

Income tax years for 2014 through 2016 have been remitted timely and remain open to examination by the taxing authorities. The tax return for fiscal 2017 has not yet been filed. The Company has been assessed late filing penalties of $10,000 per year, as well as accrued interest thereon, for each of the late filed returns for the periods from inception to December 31, 2012. Prior to a change in control at the close of fiscal 2013, prior management had not timely filed their annual tax returns.  We have estimated and accrued penalties of $80,000 as taxes payable in our financial statements. The Company has retained a tax professional to assist in reaching a settlement with the IRS.

Basic and Diluted Loss per Share

The Company reports earnings per share in accordance with FASB ASC 260, "Earnings Per Share." FASB ASC 260 requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company had potentially dilutive securities outstanding (convertible debt and liabilities) for the period ended March 31, 2018 and December 31, 2017, respectively, however, since the Company reflected a net loss in the three months ended March 31, 2018 and 2017, the effect of considering any common stock equivalents, if outstanding, would have been anti-dilutive. A separate computation of diluted earnings (loss) per share is not presented. 

	March 31, 2018		December 31, 2017
Convertible debt at $0.03 per share		24,052,133		-
Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options		500,000		500,000
Common stock issuable upon exercise of stock options		38,000,000		28,000,000
Total		62,552,133		28,500,000

Comprehensive Income

FASB ASC 220, "Comprehensive Income", establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income, as defined, includes all changes in equity during a period, exclusive of shareholder transactions. Accordingly, comprehensive income (loss) may include certain changes in shareholders' equity (deficit) that are excluded from net income (loss).

Segment Reporting

FASB ASC 820 "Segments Reporting" establishes standards for reporting information about operating segments on a basis consistent with the Company's internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. Our proposed business segments are expected to span more than one geographical area. Specifically, the Company intends to operate prosthetic and orthotic rehabilitation clinics with various European based locations, as well as a corporate development and technology center which will undertake ongoing research and marketing activities.

Fair Value of Measurements

Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2: Input other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company.

Level 3: Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability.

An asset or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities.

Recent Issued Accounting Pronouncements

There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company's operations, financial position or cash flows.

XML

Prepaid Expenses

3 Months Ended

Mar. 31, 2018

Prepaid Expenses [Abstract]

PREPAID EXPENSES

Note 5 - PREPAID EXPENSES

Prepaid expenses consist of the following: 

	March 31, 2018		December 31, 2017
Office lease, including security deposits	$	41,134	$	39,582
Travel advances and other expenses		11,808		10,943
Total prepaid expense	$	52,942	$	50,525

XML

Property and Equipment

3 Months Ended

Mar. 31, 2018

Property and Equipment [Abstract]

PROPERTY AND EQUIPMENT

Note 6 - PROPERTY AND EQUIPMENT

Property and improvements consisted of the following as of March 31, 2018 and December 31, 2017:

	March 31, 2018			December 31, 2017
Cost
Leasehold improvements	$	211,628		$	203,990
Furniture and fixture		33,967			32,781
Computers and equipment		35,406			33,144
Vehicle		61,608			59,902
Machine and plant		9,577			9,206
Lab equipment		35,497			34,123
		387,683			373,146
Less: accumulated depreciation and impairment		(246,486	)		(218,117	)
	$	141,197		$	155,029

Leasehold improvements are amortized over the term of the lease: three to ten years.

Furniture is depreciated over three to five years and computer and equipment is depreciated over three years.

Vehicles are depreciated over five years.

Machine equipment and lab equipment are depreciated over 4 years.

Depreciation expense amounted to $19,455 and $20,908 for the three months ended March 31, 2018 and 2017, respectively.

XML

Office Lease

3 Months Ended

Mar. 31, 2018

Office Lease [Abstract]

OFFICE LEASE

 Note 7 - OFFICE LEASE

Office in Greece

On February 3, 2014, the Company leased office space in Paleo Faliro, Greece on a three-year lease, commencing on March 1, 2014 and ending on February 28, 2017. The monthly rental fee is $1,900 (EUR € 1,554) including applicable taxes in the first year. Thereafter, for every further lease year and for the whole duration of the lease agreement, as well as in case of compulsory statutory extension or extension by tacit agreement, the monthly rent shall be annually adjusted by a percentage equal to the Consumer Price Index of the adjustment month with respect to the respective month of the year before (simple annual rate of change), as this is calculated by the Hellenic Statistical Authority (ELSTAT), plus two (2) percentage points (+2%).

Under the term of the lease agreement, the Company paid a total of $25,010 (EUR €18, 540) including $4,047 (EUR €3,000) for a deposit and $20,963 (EUR €15,540) for ten months' rental fee upon executing the agreement. As of March 31, 2018, $3,697 (EUR €3,000) is shown as deposits in the prepaid account.  The lease has been renewed effective June 13, 2017 for a term of 3 years terminating on February 28, 2020 at a rate of $1,960 (EUR€1,592) plus a fee of 3.6% 

Clinic in Greece

On December 29, 2014, the Company leased office space at Peania Region of Attica in Greece on a ten-year lease, commencing on January 1, 2015 and ending on October 5, 2024. The monthly rental fee is $6,996 (EUR €6,233) plus applicable taxes and the monthly operating cost estimate is $1,120 (EUR €997).

Under the term of the lease agreement, the Company paid a total of $13,991 (EUR €12,465) as deposits in the prepaid account. 

On October 9, 2015, the terms of the lease were amended to include the following provisions:

-  Effective September 1, 2015, the monthly rental fee shall be reduced to $3,500 (EUR €3,116) for a period of 12 months ending August 31, 2016.

-  In the event that the Lessee commences leasehold improvements prior to August 31, 2016, it shall inform the Lessor respectively and pay retroactively the remaining balance of the total amount of monthly rental in full from the period commencing September 1, 2015, as if they have not been reduced;

-  In the event that the Company does not proceed with leasehold improvements in the 12-month period, the lease agreement will terminate and the Lessor with retain the deposit.

-  The Lessor until such time as the leasehold improvements commence, may at any time and without indemnity terminate the lease agreement with a 30-day prior written notice to the Lessee.

As of December 31, 2016, the Company and the Lessor concluded the Termination of Lease Agreement dated August 1, 2016, and the Lessor waived all maintenance charges and utility charges for fiscal 2016. The following table is the summary of balance owing to Lessor as at March 31, 2018 and December 31, 2017:

	March 31, 2018			December 31, 2017
Amount owed for maintenance charges		$	16,700		$	16,238
Amount owed for utility charges			17,287			16,807
		$	33,987		$	33,045

Lease in UK

On March 2, 2015, the Company entered into a lease agreement for a modern, stand-alone 5,300 square foot facility in Glasgow, Scotland with an entry date of March 1, 2015. The building will host the Company's first Viocare center, a full-service Prosthetic and Orthotic ("P&O") practice with a superior standard of personalized care. The renovations to the clinic were completed in June, and the facility was opened on August 1, 2015 with an official ribbon cutting on 25 September 2015. During the first year from the date of entry, the lease fees are USD$28,000 (GBP £20,000) per annum (exclusive of VAT). On the second anniversary of the date of entry, the lease will increase to USD$56,000 (GBP £40,000) per annum (exclusive of VAT). In the third anniversary of the date of entry, the lease will be USD$56,000 (GBP £40,000) per annum (exclusive of VAT). In the fourth anniversary of the date of entry, the lease will decrease to USD$42,000 (GBP £30,000) per annum (exclusive of VAT). In the fifth anniversary of the date of entry, the lease will be USD$56,000 (GBP £40,000) per annum (exclusive of VAT).

Under the term of the lease agreement, the Company paid a total of $28,075 (GBP £20,000) as security deposits which amount is included on the Company's balance sheet in prepaid expenses. 

Location	March 31, 2018		December 31, 2017
Greece	$	3,697	$	3,594
UK		37,437		35,988
	$	41,134	$	39,582

As of March 31, 2018, the approximate future aggregate minimum lease payments in respect of our current obligations were as follows: 

Location	Greece		United Kingdom
2018		17,200		33,340
2019		23,000		53,810
2020		3,800		9,360
	$	44,000	$	96,510

XML

Loans

3 Months Ended

Mar. 31, 2018

Loans [Abstract]

LOANS

Note 8 -   LOANS

On January 5, 2017, HCi Viocare Clinics Hellas S.A., the Company's subsidiary, entered into a loan agreement with a third party to borrow a total of EUR 40,000 (US$49,287) with an annual interest rate of 5%, payable within one year from the date of the agreement. As at March 31, 2018 and December 31, 2017 a total of $52,325 and $50,276, respectively, including accrued interest to date, remained due and payable in respect of this loan. Interest expenses of $614 were accrued in the three months ended March 31, 2018. The loan was not repaid in January 2018 and is currently in default.

XML

Commitments

3 Months Ended

Mar. 31, 2018

Commitments [Abstract]

COMMITMENTS

Note 9 -   COMMITMENTS

(1) Consulting Agreement with Dr. Christos Kapatos

On April 16, 2014, the Company entered into a Consulting Agreement with Christos Kapatos whereby he will provide his services as Chief Technical Officer for the Company and the Company's wholly-owned subsidiaries.  The contract has a term of one year, renewable for such further term as may be mutually agreed between the parties. In the case that a research and development project is initiated and completed during the term of the agreement, Kapatos shall receive one million four hundred thousand (1,400,000) shares of the Company's common stock for each research project completed with a valuation less than twenty million dollars ($20,000,000 USD), three million five hundred thousand (3,500,000) shares of the Company's common stock for each research project completed with a valuation equal or greater than twenty million US dollars ($20,000,000 USD). Details of compensation under the terms of the consulting agreement are included in Note 10(ii).

(2) Consulting Agreement with JAMB

Effective July 10, 2017, the Company entered into a business consulting agreement (the "Consulting Agreement") with JAMB Group LLC. ("Consultant") for services to commence July 15, 2017 and to continue for a period of twelve (12) months thereafter. Under the terms of the Agreement, the Consultant shall provide consulting services to the Company for the development and expansion of its business, including the introduction to specific Targets for the purposes of financing transactions or other business relationship. The Consultant is entitled to compensation for the provision of services in the form of 500,000 shares of the common stock which were issued upon execution of the Consulting Agreement, as well as certain other fees and consideration. 

500,000 shares have been valued at $79,950, the fair market value of $0.1599 per share, on issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017.

(3) Consulting Agreement with Mr. Stefanos Batzakis

On September 1, 2017, the Company entered into a one-year consulting agreement (the "Agreement") with Mr Stefanos Batzakis. As per terms of said Agreement Batzakis will provide services to the Company as IT Solutions Manager, for a term of one (1) year and receive compensation in the form of stock, namely five hundred thousand (500,000) common shares, which were issued upon signing of this Agreement.

500,000 shares have been valued at $40,000, the fair market value of $0.08 per share on issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017

(4) Consulting Agreement with Dr. Ioannis Doupis

On October 9, 2017, the Company appointed Dr. Ioannis Doupis, to the Advisory Board of the Company originally formed on April 15, 2014 and Concurrently entered into an advisory board agreement. Compensation shall be the grant of a total of 500,000 shares of the Company's common stock valued at the fair market price on the date of grant of $0.07 per share. The advisory board appointment is for a term of one year.

500,000 shares have been valued at $35,000, the fair market value of $0.07 per share on issue date, which amount has been expensed as consulting expenses in the year ended December 31, 2017

(5) Consulting Agreement with Ms. Paraskevi Pilarinou

On December 12, 2017, the Company entered into a consulting agreement (the "Agreement") with an Ms. Paraskevi Pilarinou (the "Consultant").  Under the terms and conditions of the Agreement the Consultant shall be employed in the position of Financial Controller of the Company. The Agreement has a three-year term starting on January 2, 2018 and ending on January 1, 2021 and the Consultant shall be remunerated with a monthly fee of EUR2,000 (IUSD$2,460) and was issued 2,000,000 shares of the Company's common stock. The 2,000,000 shares were issued as compensation as of the date of the agreement and were valued at $0.05 per share or $100,000, the fair market value on the date of issuance in the year ended December 31, 2017.

(6) Consulting Agreement with Charalampos Sgardelis

On January 2, 2017, the Company entered into a one-year consulting agreement (the "Agreement") with Mr. Charalampos Sgardelis ("Sgardelis"). Under the terms of the Agreement, Sgardelis provides services to the Company as Business Development Manager, for a term of one (1) year and receives compensation of Two Thousand Euros (2,000 €) per month.

On February 26, 2018 the Company approved a three (3) year extension to the Agreement (the "Addendum") between the Company and Sgardelis.  Under the terms and conditions of the Addendum, Sgardelis is entitled to receive compensation of Three Thousand Euros (3,000 €) per month and shall be awarded five million (5,000,000) common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $0.049 per share for total consideration of $245,000.

(7) Advisory Agreement with Ravi Vaidyanathan

On March 27, 2018, the Company entered into a one-year advisory agreement (the "Agreement") with an Mr. Ravi Vaidyanathan (the "Advisor"). Under the terms and conditions of the Agreement, the Advisor is appointed to the Company's Scientific Advisory Board and is entitled to remuneration for the provision of services in the form of 500,000 shares of the common stock to be issued upon signing of the Agreement. Further, the Advisor shall be granted additional 250,000 shares of the common stock to be issued after a time-period of six (6) months from the signing of the Agreement.  The Advisor shall serve on the Scientific Advisory Board in the position of Biomechatronics and Human Augmentation Advisor. The Company or the Advisor may terminate the agreement upon 30 days written notice.  The issued shares were valued at fair market value on the date of issuance or $0.055 per share for total consideration of $27,500.

XML

Related Party Transactions

3 Months Ended

Mar. 31, 2018

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

Note 10 -   RELATED PARTY TRANSACTIONS

The following table provides details of the Company's related party transactions during the three months ended March 31, 2018 and 2017

(a) Services provided from related parties:

	Three Months ended March 31,
	2018		2017
Consulting fees from CEO and President (i)	$	38,867	$	30,000
Consulting fees from a Director (ii)		15,361		10,655
Professional fees from Director (iii)		3,687		3,196
Consulting fees for VP (iv)		12,903		6,393
Stock options granted to CEO and President (i)		122,543		122,543
Stock options granted to Director (ii)		45,300		-
Stock options granted to VP (iv)		16,800		-
Stock award granted to Director (iii)		-		172,000
Stock-based compensation (VP) (iv)		-		187,200
	$	255,461	$	409,444

(i)	On September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016.   Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract.  In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR$10,000 per month.  Further, Mr. Leontaritis is entitled to acquire at his discretion 3,000,000 shares of the common stock at a price of $0.30 per share for a term of five (5) years.  The Company recognized stock-based compensation expense allocated to consulting fees of $122,543 during the three months ended March 31, 2018 and 2017. The unrecognized amount of $1,838,151 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2019, Mr. Leontaritis is entitled to total minimum payments of EUR$210,000 (US$258,080).
(ii)	On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$49,290 (€40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company Euros €40,000 for services rendered in each fiscal year respectively. On December 12, 2017, the Company approved the issuance of 18,500,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant.  The 18,500,000 shares have been valued at $925,000, or $0.05 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$61,610) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 25,000,000 shares of the common stock at a price of $US0.05 for a term of six years. The Company recognized stock-based compensation expense allocated to consulting fees of $45,300 during the three months ended March 31, 2018. The unrecognized amount of $1,030,200 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2023, Dr. Kapatos is entitled to total minimum payments of EUR287,500 (US$353,324).
(iii)	On September 10, 2013, the Board of Directors of the Company elected Nikolaos Kardaras as Secretary and a director of the Company. During each of fiscal 2017 and fiscal 2016, Mr. Kardaras invoiced the Company EUR12,000 for services rendered in his capacity as a director which amount totaled US$13,500 and $13,300 respectively. On March 3, 2017, the Company approved the issuance of 1,000,000 common shares for the services provided by Mr. Nikolaos Kardaras in the form of a stock award which vested as of the date of grant. 1,000,000 shares have been valued at $172,000, the fair market value of $0.172 per share on issue date, which amount has been expensed as stock based compensation.

(iv) On September 1, 2015, the Board of Directors of the Company approved a consulting agreement with Sergios Katsaros and appointed Mr. Katsaros Vice President. Under the terms of the consulting agreement, Mr. Katsaros will work directly with the Company's President and CEO in order to create and implement the Company's strategic plan and assist in securing additional financing to meet the needs of the Company's business plan and corporate objectives.  The initial term of the contract is six months and Mr. Katsaros will receive compensation of USD$2,460 (€2,000) per month. On March 1, 2016, the Company approved a one-year extension to the consulting agreement and the Company approved the grant of a stock award of 300,000 common shares as compensation for the services provided by Vice President, Sergios Katsaros.  The award vests in three equal instalments of 100,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. During fiscal 2016 a total of $169,000 in respect of 200,000 vested shares was recorded as stock based compensation. On March 1, 2017, the final instalment of 100,000 shares were issued in accordance with the terms of the award valued at $17,200, the fair market value on grant date, which amount has been expensed as stock-based compensation in 2017.   On March 17, 2017, the Company approved the issuance of a further 1,000,000 common shares for the services provided by Mr. Katsaros, in the form of a stock award which vested as of the date of grant. 1,000,000 shares have been valued at $170,000, the fair market value of $0.17 per share on grant date, which amount has been expensed as stock-based compensation.   On December 12, 2017 the Company approved a three-year extension to the consulting agreement between the Company and Mr. Katsaros effective as of January 2, 2018.  The revision to the Agreement has a term of three years, being effective as of January 2, 2018, and ending on January 1, 2021, renewable for such further term as may be mutually agreed between the parties. Mr. Katsaros shall be remunerated with a monthly stipend of EUR3,500 (US$4,310), and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Mr. Katsaros shall also be entitled to acquire at his discretion 10,000,000 shares of the common stock at a price of $US0.05 for a term of five years commencing January 2, 2018.   The Company recognized stock-based compensation expense allocated to consulting fees of $16,800 during the three months ended March 31, 2018. The unrecognized amount of $320,300 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2021, Mr. Katsaros is entitled to total minimum payments of EUR115,500 (US$141,944).

(b) Accounts payable and accrued liabilities from related parties:

	March 31,			December 31,
	2018			2017
CEO and President (i)	$	306,423		$	413,010
Director (ii)		116,229			95,843
Director (iii)		863			-
VP (iv)		1,848			-
Reclassification to Convertible Debt, Related parties		(422,652	)
	$	2,711		$	508,853

(c) Advances from related parties:

	March 31,			December 31,
	2018			2017
CEO and President (i)	$	283,191		$	287,073
Director (ii)		15,721			54,282
Reclassification to Convertible Debt, Related Parties		(298,912	)
	$	-		$	341,355

(d) Convertible Debt, related parties:

On February 15, 2018, the Company and certain shareholders holding in excess of 5% of the Company's common stock and concurrently holding a position on the Company's Board, or acting in the capacity of any officer of the Company or its subsidiaries, agreed that repayment against pre-existing debt payable by the Company on the agreement date shall be  suspended until such time as  the Company concludes a full profitable year of operations. Further the parties agreed that any such pre-existing debt or portion thereof shall be convertible at any time into restricted shares of the Company's common stock at a price equal or greater to $0.03 per share. On the date of the agreement the fair market value of the Company's common stock as traded on OTCMarkets was $0.0403 per share. The Company accounted for this transaction by applying ASC 470-20-35.  As the convertible debt has no stated redemption date, the Company will recognize the discount as interest expense on the earliest conversion date.  

The Company has reclassified all debts payable as of February 15, 2018 to our CEO and CTO from advances and accounts payable, related party, to convertible debt, related party.  At March 31, 2018 a total of $721,564 in debt   was convertible into 24,052,133 shares of restricted common stock.

XML

Capital Stock

3 Months Ended

Mar. 31, 2018

Capital Stock [Abstract]

CAPITAL STOCK

Note 11 -   CAPITAL STOCK

The Articles of Incorporation authorize the Company to issue 5,000,000 shares of preferred stock with a par value of $0.0001, and 700,000,000 shares of common stock with a par value of $0.0001.  No shares of preferred stock have been issued, however, the Company has granted 25,000 fully vested stock options for the purchase of 25,000 shares of Series A Preferred Stock of the Company at a price of $0.04 per share for a period of five (5) years from the date of vesting. (ref: Note 13 below) 

Share issuances during the three months ended March 31, 2018

During the three months ended March 31, 2018, 12,148,168 shares of common stock were issued in respect of various private placements for total cash proceeds of $359,381.

During the three months ended March 31, 2018, the Company issued 5,500,000 shares to employees, board members and consultants valued at $272,500, for services rendered.  The Company valued these issuances based on the closing price of the Company's stock as reflected on the OTC Markets on the respective dates of issuance.

Designation of Series A Preferred Stock

On January 13, 2014, the Company filed a Certificate of Designation with the Secretary of State of the State of Nevada.   The Certificate of Designation sets forth the rights, preferences and privileges of a class of the Company's preferred stock.  Such class shall be designated as the "Series A Preferred Stock" and the number of shares constituting such series shall be 5,000,000 shares.  The holders of Series A Preferred Stock will be entitled to a preference over all of the shares of the Company's common stock.  Holders of Series A Preferred Stock shall have 50 votes per share of Series A Preferred Stock held by them and shall be entitled to notice of any stockholders' meeting and to vote as a single class upon any matter submitted to the stockholders for a vote.  Each share of Series A Preferred Stock is convertible into 20 shares of our common stock at any time at the holder's option.  Shares of Series A Preferred Stock shall not be entitled to any dividends.  The preferred stock shall be entitled to a preference over all of the shares of common stock of the Company with respect to the distribution of assets in the event of the liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs.

XML

Stock Options

3 Months Ended

Mar. 31, 2018

Stock Options [Abstract]

STOCK OPTIONS

Note 12 - STOCK OPTIONS

A total of 25,000 stock options granted during April and June of fiscal 2014 entitling each holder the right to purchase a total of 5,000 shares of Series A Preferred Stock of the Company at a price of $0.04 per share for a period of five (5) years remain unexercised and outstanding as at March 31, 2018.  The Series A Preferred shares are convertible on the basis of 20 shares of common stock for each one share held and have voting rights of 50 votes per share of Series A Preferred stock held at any meetings of the stockholders.

On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019. Further, Mr. Leontaritis is entitled to acquire at his discretion 3,000,000 shares of the common stock at a price of $0.30 per share for a term of five (5) years.

On December 12, 2017, Dr. Christos Kapatos, director, was issued a stock option as part of an extension to his employment contract whereunder, at his discretion, he may to acquire 25,000,000 shares of the common stock at a price of $US0.05 for a term of six years.

Mr. Katsaros shall also be entitled to acquire at his discretion 10,000,000 shares of the common stock at a price of $US0.05 for a term of five years commencing January 2, 2018.

The Company accounts for share-based payments pursuant to ASC 718, "Stock Compensation" and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company's stock price and expected dividends.

Stock compensation expense for stock options is recognized over the vesting period of the award.

The Company recognized stock-based compensation expense allocated to consulting fees of $184,643 and $122,543 during the three months ended March 31, 2018 and 2017, respectively. The unrecognized amount of $3,188,651 will be expensed in future periods.

The following table summarizes information concerning stock options outstanding as of March 31, 2018, and December 31, 2017:

Series A Preferred Stock:

	March 31, 2018				December 31, 2017
	Series A Preferred stock		Weighted Average Exercise Price $		Series A Preferred stock		Weighted Average Exercise Price $
Outstanding at beginning of the year		25,000		0.04		25,000		0.04
Granted		-		-		-		-
Exercised		-		-		-		-
Expired or canceled		-		-		-		-
Outstanding at the period		25,000		0.04		25,000		0.04

The aforementioned options have an average remaining life of 1.07 years. 

Common stock:

	March 31, 2018				December 31, 2017
	Common stock		Weighted Average Exercise Price $		Common stock		Weighted Average Exercise Price $
Outstanding at beginning of the year		28,000,000		0.076		-		-
Granted		10,000,000		0.05		28,000,000		0.076
Exercised		-		-		-		-
Expired or canceled		-		-		-		-
Outstanding at the period		38,000,000		0.070		28,000,000		0.076

The aforementioned options have an average remaining life of 5.55 years. 

Valuation Assumptions

The Company accounts for share-based payments pursuant to ASC 718, "Stock Compensation" and, accordingly, the Company records compensation expense for share-based awards based upon an assessment of the grant date fair value for stock options using the Black-Scholes option pricing model. The fair value of stock options under the Black-Scholes model requires management to make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company's stock price and expected dividends.

Stock compensation expense for stock options is recognized over the vesting period of the award.

The following table presents the range of the weighted average fair value of options granted and the related assumptions used in the Black-Scholes model for stock option grants:

Series A Preferred Stock: 

	Options Granted September 30, 2014
Fair value of options granted	1.40 ~ 2.00
Assumptions used:
Expected life (years) (a)		1.00
Risk free interest rate (b)		0.11%
Volatility (c)	117.09 ~ 119.83 %
Dividend yield (d)		0.00

Common stock:

	Options Granted date
Fair value of options granted	0.038 ~ 0.925
Assumptions used:
Expected life (years) (a)	5 ~ 6
Risk free interest rate (b)	1.93% ~ 2.25%
Volatility (c)	175.40% ~ 254.86%
Dividend yield (d)	0.00

The Company utilizes the Black-Scholes option pricing model to determine the fair value of each option award. Expected volatilities are based on the historical volatility of the Company's common stock over a period consistent with that of the expected term of the options. The expected term of the options are estimated based on factors such as vesting periods, contractual expiration dates and historical exercise behavior. The risk-free rates for periods within the contractual life of the options are based on the yields of U.S. Treasury instruments with terms comparable to the estimated option terms. The dividend yield rate is not considered in the model, as the Company has not established a dividend policy for the stock.

XML

Provision for Income Taxes

3 Months Ended

Mar. 31, 2018

Provision for Income Taxes [Abstract]

PROVISION FOR INCOME TAXES

Note 13– PROVISION FOR INCOME TAXES:

The Company's operations in Greece have no tax free income threshold and are subject to taxation at a rate of 29% applied to all net income earned after $1 Euro.  Further, after its first year of profitable operations, the Company is required to remit estimated income taxes prorated monthly based on the prior year's calculated income taxes payable.

The Company's operations in the United Kingdom are subject to Corporation Tax at a single taxation rate of 20% calculated on net income.  The Company's operations are subject to certain relief from taxation with respect to R&D credit claims and may be subject to "Patent Box" relief which provides for a lower rate of income tax payable on all licensing income generated from the corporate owned patents.  There are numerous criteria required to be met to qualify for such relief.

The Company has experienced losses since inception. As a result, it has incurred no U.S. Federal income tax. The Internal Revenue Code allows net operating losses (NOL's) to be carried forward and applied against future profits for a period of twenty years. The Greece Tax Code permits such carryforwards for a period of five years. The United Kingdom Tax Code permits such carryforwards indefinitely. The total of these NOL's at March 31, 2018 was $2,891,200 in the U.S., $1,391,200 in Greece and $301,680 in the U.K.  and as at December 31, 2017 was $2,888,000 in the U.S., $1,343,400 in Greece and $307,080 in the U.K.

On December 22, 2017, the 2017 Tax Cuts and Jobs Act (the Tax Act) was enacted into law including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. While the Company has revenue we have no foreign earnings and therefore, we do not anticipate the impact of a transition tax. We have remeasured our U.S. deferred tax assets at a statutory income tax rate of 21% during fiscal 2017. Since the Tax Act was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12 months, we consider the accounting of any transition tax, deferred tax re-measurements, and other items to be incomplete due to the forthcoming guidance and our ongoing analysis of final year-end data and tax positions. We expect to complete our analysis within the measurement period in accordance with SAB 118, and no later than fiscal year end December 31, 2018.

The provision for income taxes in US consists of the following:

	Three months ended March 31,
	2018			2017
Current operations	$	99,200		$	204,457
Timing differences, Stock based compensation		(96,000	)		(132,226	)
Less, Change in valuation allowance		(3,200	)		(72,231	)
Net refundable amount	$	-		$	-

 The provision for income taxes in Greece consists of the following:

	Three months ended March 31,
	2018			2017
Current operations	$	47,800			$	15,380
Less, Change in valuation allowance		(47,800	)			(15,380	)
Net refundable amount	$	-			$	-

The provision for income taxes in UK consists of the following:

	Three months ended March 31,
	2018			2017
Current operations	$	11,200		$	16,654
Research and development		(16,600	)		(13,113	)
Less, Change in valuation allowance		5,400			(3,541
Net refundable amount	$	-		$	-

The cumulative tax effect at the expected rates in the U.S., in Greece and in the U.K. for significant items comprising our net deferred tax amounts reported in US Dollars as of March 31, 2018 and December 31, 2017 are as follows:

	March 31, 2018									December 31, 2017
	US Expected rate 21%			Greece Expected rate 29%			UK Expected rate 20%			US Expected rate 21%			Greece Expected rate 29%			UK Expected rate 20%
Deferred tax asset attributable to:
Net operating loss carryover		2,891,200			1,391,200			301,680			4,654,100			1,343,400			307,080
Change in effective tax rates		-			-			-			(1,766,100	)		-			-
Less, Valuation allowance		(2,891,200	)		(1,391,200	)		(301,680	)		(2,888,000	)		(1,343,400	)		(307,080	)
Net deferred tax asset		-			-			-			-			-

The Company has no tax position at December 31, 2017 and December 31, 2016 for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. As a result of a re-assessment of certain late tax filings completed for the fiscal years ended 2007 through 2012 the IRS has assessed late filing penalties of approximately $80,000, which we have recognized and accrued in our balance sheets at December 31, 2017. The Company had no accruals for interest and penalties at December 31, 2016. The Company is aggressively negotiating with the IRS to have a portion or all of these penalties waived in a future period. The Company's utilization of any net operating loss carry forward may be unlikely as a result of its intended activities.

The Company recognized deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carryforwards. The Company will establish a valuation allowance to reflect the likelihood of realization of deferred tax assets.

XML

Segment Reporting

3 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

SEGMENT REPORTING

Note 14 - SEGMENT REPORTING

The Company's operations are classified into two reportable segments that provide different products or services. Separate management of each segment is required because each business unit is subject to different marketing, operations, and growth and technology development strategies.

The Clinics segment derives its revenue from provision of services at our P&O Clinic located in Glasgow, Scotland. The Technology segment derives its income from the licensing of its proprietary technologies and ultimately recurring royalty income as well as technology access fees. Presently we are only deriving income from our UK-based operations.  We expect this to be the case until such time as we are able to expand our chain of P&O Clinics.

There are no inter-segment sales however, the Company's two primary operating segments do share costs on certain operational overhead including facility rent and staff salaries.

Three months ended March 31, 2018:

	Clinics (UK)		Technology (UK)			All Other (Greece)			Total
Revenue	$	126,890	$	4,890		$	-		$	131,780
Depreciation & amortization	$	2,357	$	11,247		$	5,851		$	19,455
Net (Loss) from operations	$	20,469	$	(76,551	)	$	(637,433	)	$	(693,515	)
Interest expenses	$	-	$	-		$	(614	)	$	(614	)
Assets	$	277,638	$	146,554		$	140,906		$	565,098
Expenditure on long-lived assets	$	-	$	-		$	-		$	-

Three months ended March 31, 2017:

	Clinics (UK)			Technology (UK)			All Other (Greece)			Total
Revenue	$	83,884		$	2,556		$	-		$	86,440
Depreciation & amortization	$	2,231		$	10,771		$	7,906		$	20,908
Loss from operations	$	(23,319	)	$	(58,947	)	$	(652,933	)	$	(735,199	)
Interest expenses	$	(1.040	)	$	-		$	(496	)	$	(1,536	)
Assets	$	60,154		$	158,104		$	95,480		$	313,738
Expenditure on long-lived assets	$	-		$	-		$	-		$	-

XML

Subsequent Events

3 Months Ended

Mar. 31, 2018

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

Note 16 - SUBSEQUENT EVENTS

On May 3, 2018 the Company awarded 100,000 shares of the Company's restricted common stock to Mr. Nikolaos Gemelos as consideration for his services rendered as Consultant. The shares were valued at fair market value on the date of issuance or US$0.067 per share for total consideration of $6,700.

On May 23, 2018 the Company approved an amendment to the term of the scientific advisory agreement with Dr. Christos Kapatos, board member CTO and member of the Scientific Advisory Board, originally entered into on April 15, 2014 in order to extend the term to April 15, 2019.

On May 24, 2018 the Company incorporated a wholly owned subsidiary for purposes of completing a merger and name change from HCi Viocare to Rafina Innovations, Inc. Concurrently the Company's Board of Directors approved a reverse share split on the basis 20 for 1.  Upon effect of the reverse split, our authorized capital will decrease from 700,000,000 shares of common stock to 35,000,000 shares of common stock and correspondingly, our current issued and outstanding shares of common stock will decrease from 259,762,025 to approximately 12,988,101 shares of common stock, all with a par value of $0.0001.  Our preferred shares will remain unchanged.  The Company has filed the agreement and plan of merger as well as the articles of amendment with the State of Nevada and the Financial Industry Regulatory Authority ("FINRA").  

The Company's trading symbol will remain unchanged and is OTCMarkets:VICA.  The Company's CUSIP will change to 75063R106.

The Company expects the aforementioned transactions to become effective on July 3, 2018. We will announce the completion of FINRA review and the effectiveness of these changes on the market by filing a Current Report on Form 8-K.

On May 31, 2018, the Company entered into a Debt Settlement and Subscription Agreement with the President of the Company, Mr. Sotirios Leontaritis. At March 31, 2018, the Company was indebted to Leontaritis in the amount of US$589,614 in respect to certain unpaid salary, advances for operational shortfalls and certain unsettled expense reimbursements. Leontaritis has agreed to accept 3,333,333 shares of the Company's common stock at a price of US$0.03 per share to settle US$100,000 of the debt pursuant to the terms and conditions set forth in the agreement.

On June 7, 2018, the Company entered into a six-month services agreement with Mr. Georgios Dritsoulas. As per terms of said Agreement, Mr. Dritsoulas will provide services to the Company as Consultant for the development and expansion of the Company's business for a term of six (6) months. Mr. Dritsoulas received compensation of fifty thousand (50,000) restricted common shares as compensation for the services provided.

On June 11, 2018, the Company entered into a Private Placement Subscription Agreement with Mr. Constantinos Zertalis, Director and beneficial owner of our controlling shareholder, Maschari Ltd. ("Maschari"). Under the terms of the Agreement Mr. Zertalis subscribed directly for a total of 294,840 shares of the Company's common stock at a purchase price of US$0.05 per share for total cash proceeds of US$14,724. The shares are subject to applicable resale restrictions.  Prior to the aforementioned subscription agreement, Mr. Zertalis owned 122,710,562 shares of the common stock of HCi Viocare indirectly through Maschari, and 986,815 shares of the Company's common stock directly.

The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there are no additional subsequent events to disclose.

XML

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2018

Summary of Significant Accounting Policies [Abstract]

Principals of Consolidation

Principals of Consolidation

The consolidated financial statements include the accounts of HCi Viocare and its wholly-owned subsidiaries, HCi Viocare Technologies Limited, HCi Viocare Clinics UK Limited and HCi Viocare Clinics (Hellas) S.A. On August 2, 2017 the Company commenced the dissolution and liquidation of HCi Viocare Clinics (Hellas) S.A. All significant intercompany balances and transactions have been eliminated.

Basis of Presentation

Basis of Presentation

The interim unaudited financial information referred to above has been prepared and presented in conformity with accounting principles generally accepted in the United States applicable to interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The interim financial information has been prepared on a condensed basis, such that certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission. These interim financial statements include all adjustments that, in the opinion of management, are necessary in order to make the financial statements not misleading.

This report on Form 10-Q should be read in conjunction with the Company's financial statements and notes thereto included in the Company's Form 10-K for the fiscal year ended December 31, 2017 filed on May 17, 2018. Results of the three ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ended December 31, 2018 and any other future periods.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results when ultimately realized could differ from these estimates.

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits in banks with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and which have original maturities of three months or less.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The carrying value of financial instruments including cash and cash equivalents, receivables, prepaid expenses, accounts payable and accrued expenses, approximates their fair value due to the relatively short-term nature of these instruments.

Foreign Currencies

Foreign Currencies

Items included in the consolidated financial statements of each of the Company and its subsidiaries are measured using the currency of the primary economic environment in which the entity operates (the 'functional currency').  The Company's reporting currency is the U.S. dollar.  The functional currency of subsidiaries based in the UK is pound sterling and the functional currency of the Company's subsidiary based in the Greece is the Euro. All transactions initiated in Pounds and Euro are translated into U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830-30, "Translation of Financial Statements," as follows:

i) assets and liabilities are translated at the closing rate at the date of the balance sheet, or

     1USD=0.81158EUR, 1USD=0.71239GBP (March 31, 2018), and;

1USD=0.8347EUR, 1USD=0.74108GBP (December 31, 2017);

ii) income and expenses are translated at average exchange rates for three months ended March 31, or

         1USD=0.8137EUR, 1USD=0.7189GBP (March 31, 2018), and;

1USD=0.93136EUR, 1USD=0.80731GBP (March 31, 2017);

iii)  all resulting exchange differences are recognized as other comprehensive income, a separate component of equity.

Adjustments arising from such translations are included in accumulated other comprehensive income (loss) in stockholders' equity.

Revenue Recognition

Revenue Recognition

Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectibility of the fee is reasonably assured.

The Company recognizes revenue when the earnings process is complete and persuasive evidence of an arrangement exists. This generally occurs for revenue recorded in our P&O Clinics division when prosthetic products are fitted to customers, both title and the risks and rewards of ownership are transferred or services have been rendered and accepted, the selling price is fixed or determinable, and collectibility is reasonably assured.  Revenue is recognized upon issuance of an invoice and completion of each concluded stage of work performed on a prosthetic product.  The Company recognizes revenue from its technology licensing fees and/or product development fees upon conclusion of services provided under contract.

There was no impact on the Company's financial statements as a result of adopting Topic 606 for the three months ended March 31, 2018 and 2017, or the fiscal year ended December 31, 2017.

Inventory

Inventory

Inventories, which consist principally of raw materials and parts, are stated at the lower of cost or market. Cost is determined using the first-in, first-out method and are adjusted to actual cost quarterly based on a physical count. Net realizable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. Work-in-process inventory consists of materials, labor and a predetermined fixed rate of overhead which is valued based on established standards for the stage of completion of each custom order. We do not carry finished goods on hand. Material, labor and overhead costs are determined at the individual clinic level. Presently we only maintain very limited parts and raw materials inventory.

Warranty

Warranty

We do not record warranty liabilities at the time of sale for the estimated costs that may be incurred under the terms of the applicable limited warranty as all component parts are covered by our respective industry suppliers.

Advertising Costs

Advertising Costs

The Company expenses advertising costs as incurred or the first time the advertising takes place, whichever is earlier, in accordance with ASC 720-35. Advertising costs were immaterial for the three months ended March 31, 2018 and 2017, respectively.

Research and Development Costs

Research and Development Costs

The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, "Research and Development". Research and development costs were $83,328 and $78,066 for the three months ended March 31, 2018 and 2017, respectively.

Related parties

Related parties

For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.

Stock-based compensation

Stock-based compensation

For stock-based compensation, the Company follows the guidance codified in the Compensation – Stock Compensation Topic of FASB ASC ("ASC 718"). The Company determines the value of stock issued at the date of grant. It also determines at the date of grant, the value of stock at fair market value or the value of services rendered (based on contract or otherwise) whichever is more readily determinable.

Income Taxes

Income Taxes

The Company accounts for income taxes in accordance with FASB ASC 740, "Income Taxes", which requires the asset and liability approach for financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company has a retained deficit from operations. Because there is no certainty that we will realize taxable income in the future, the Company did not record any deferred tax benefit as a result of these losses and recorded a valuation allowance offsetting the entire potential tax benefit.

Income tax years for 2014 through 2016 have been remitted timely and remain open to examination by the taxing authorities. The tax return for fiscal 2017 has not yet been filed. The Company has been assessed late filing penalties of $10,000 per year, as well as accrued interest thereon, for each of the late filed returns for the periods from inception to December 31, 2012. Prior to a change in control at the close of fiscal 2013, prior management had not timely filed their annual tax returns.  We have estimated and accrued penalties of $80,000 as taxes payable in our financial statements. The Company has retained a tax professional to assist in reaching a settlement with the IRS.

Basic and Diluted Loss per Share

Basic and Diluted Loss per Share

The Company reports earnings per share in accordance with FASB ASC 260, "Earnings Per Share." FASB ASC 260 requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company had potentially dilutive securities outstanding (convertible debt and liabilities) for the period ended March 31, 2018 and December 31, 2017, respectively, however, since the Company reflected a net loss in the three months ended March 31, 2018 and 2017, the effect of considering any common stock equivalents, if outstanding, would have been anti-dilutive. A separate computation of diluted earnings (loss) per share is not presented. 

	March 31, 2018		December 31, 2017
Convertible debt at $0.03 per share		24,052,133		-
Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options		500,000		500,000
Common stock issuable upon exercise of stock options		38,000,000		28,000,000
Total		62,552,133		28,500,000

Comprehensive Income

Comprehensive Income

FASB ASC 220, "Comprehensive Income", establishes standards for reporting and display of comprehensive income, its components and accumulated balances. Comprehensive income, as defined, includes all changes in equity during a period, exclusive of shareholder transactions. Accordingly, comprehensive income (loss) may include certain changes in shareholders' equity (deficit) that are excluded from net income (loss).

Segment Reporting

Segment Reporting

FASB ASC 820 "Segments Reporting" establishes standards for reporting information about operating segments on a basis consistent with the Company's internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. Our proposed business segments are expected to span more than one geographical area. Specifically, the Company intends to operate prosthetic and orthotic rehabilitation clinics with various European based locations, as well as a corporate development and technology center which will undertake ongoing research and marketing activities.

Fair Value of Measurements

Fair Value of Measurements

Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2: Input other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company.

Level 3: Unobservable inputs. Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability.

An asset or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities.

Recent Issued Accounting Pronouncements

Recent Issued Accounting Pronouncements

There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company's operations, financial position or cash flows.

XML

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Summary of Significant Accounting Policies [Abstract]

Schedule of computation of diluted earnings (loss) per share

	March 31, 2018		December 31, 2017
Convertible debt at $0.03 per share		24,052,133		-
Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options		500,000		500,000
Common stock issuable upon exercise of stock options		38,000,000		28,000,000
Total		62,552,133		28,500,000

XML

Prepaid Expenses (Tables)

3 Months Ended

Mar. 31, 2018

Prepaid Expenses [Abstract]

Schedule of prepaid expenses

	March 31, 2018		December 31, 2017
Office lease, including security deposits	$	41,134	$	39,582
Travel advances and other expenses		11,808		10,943
Total prepaid expense	$	52,942	$	50,525

XML

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2018

Property and Equipment [Abstract]

Schedule of property and improvements

	March 31, 2018			December 31, 2017
Cost
Leasehold improvements	$	211,628		$	203,990
Furniture and fixture		33,967			32,781
Computers and equipment		35,406			33,144
Vehicle		61,608			59,902
Machine and plant		9,577			9,206
Lab equipment		35,497			34,123
		387,683			373,146
Less: accumulated depreciation and impairment		(246,486	)		(218,117	)
	$	141,197		$	155,029

XML

Office Lease (Tables)

3 Months Ended

Mar. 31, 2018

Office Lease [Abstract]

Summary of balance owing to lessor

	March 31, 2018			December 31, 2017
Amount owed for maintenance charges		$	16,700		$	16,238
Amount owed for utility charges			17,287			16,807
		$	33,987		$	33,045

Schedule of security deposits paid under the term of the lease agreement

Location	March 31, 2018		December 31, 2017
Greece	$	3,697	$	3,594
UK		37,437		35,988
	$	41,134	$	39,582

Schedule of approximate future aggregate minimum lease payments

Location	Greece		United Kingdom
2018		17,200		33,340
2019		23,000		53,810
2020		3,800		9,360
	$	44,000	$	96,510

XML

Related Party Transactions (Tables)

3 Months Ended

Mar. 31, 2018

Related Party Transactions [Abstract]

Schedule of services provided from related parties

	Three Months ended March 31,
	2018		2017
Consulting fees from CEO and President (i)	$	38,867	$	30,000
Consulting fees from a Director (ii)		15,361		10,655
Professional fees from Director (iii)		3,687		3,196
Consulting fees for VP (iv)		12,903		6,393
Stock options granted to CEO and President (i)		122,543		122,543
Stock options granted to Director (ii)		45,300		-
Stock options granted to VP (iv)		16,800		-
Stock award granted to Director (iii)		-		172,000
Stock-based compensation (VP) (iv)		-		187,200
	$	255,461	$	409,444

(i)	On September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016.   Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract.  In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR$10,000 per month.  Further, Mr. Leontaritis is entitled to acquire at his discretion 3,000,000 shares of the common stock at a price of $0.30 per share for a term of five (5) years.  The Company recognized stock-based compensation expense allocated to consulting fees of $122,543 during the three months ended March 31, 2018 and 2017. The unrecognized amount of $1,838,151 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2019, Mr. Leontaritis is entitled to total minimum payments of EUR$210,000 (US$258,080).
(ii)	On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$49,290 (€40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company Euros €40,000 for services rendered in each fiscal year respectively. On December 12, 2017, the Company approved the issuance of 18,500,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant.  The 18,500,000 shares have been valued at $925,000, or $0.05 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$61,610) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 25,000,000 shares of the common stock at a price of $US0.05 for a term of six years. The Company recognized stock-based compensation expense allocated to consulting fees of $45,300 during the three months ended March 31, 2018. The unrecognized amount of $1,030,200 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2023, Dr. Kapatos is entitled to total minimum payments of EUR287,500 (US$353,324).
(iii)	On September 10, 2013, the Board of Directors of the Company elected Nikolaos Kardaras as Secretary and a director of the Company. During each of fiscal 2017 and fiscal 2016, Mr. Kardaras invoiced the Company EUR12,000 for services rendered in his capacity as a director which amount totaled US$13,500 and $13,300 respectively. On March 3, 2017, the Company approved the issuance of 1,000,000 common shares for the services provided by Mr. Nikolaos Kardaras in the form of a stock award which vested as of the date of grant. 1,000,000 shares have been valued at $172,000, the fair market value of $0.172 per share on issue date, which amount has been expensed as stock based compensation.

(iv) On September 1, 2015, the Board of Directors of the Company approved a consulting agreement with Sergios Katsaros and appointed Mr. Katsaros Vice President. Under the terms of the consulting agreement, Mr. Katsaros will work directly with the Company's President and CEO in order to create and implement the Company's strategic plan and assist in securing additional financing to meet the needs of the Company's business plan and corporate objectives.  The initial term of the contract is six months and Mr. Katsaros will receive compensation of USD$2,460 (€2,000) per month. On March 1, 2016, the Company approved a one-year extension to the consulting agreement and the Company approved the grant of a stock award of 300,000 common shares as compensation for the services provided by Vice President, Sergios Katsaros.  The award vests in three equal instalments of 100,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. During fiscal 2016 a total of $169,000 in respect of 200,000 vested shares was recorded as stock based compensation. On March 1, 2017, the final instalment of 100,000 shares were issued in accordance with the terms of the award valued at $17,200, the fair market value on grant date, which amount has been expensed as stock-based compensation in 2017.   On March 17, 2017, the Company approved the issuance of a further 1,000,000 common shares for the services provided by Mr. Katsaros, in the form of a stock award which vested as of the date of grant. 1,000,000 shares have been valued at $170,000, the fair market value of $0.17 per share on grant date, which amount has been expensed as stock-based compensation.   On December 12, 2017 the Company approved a three-year extension to the consulting agreement between the Company and Mr. Katsaros effective as of January 2, 2018.  The revision to the Agreement has a term of three years, being effective as of January 2, 2018, and ending on January 1, 2021, renewable for such further term as may be mutually agreed between the parties. Mr. Katsaros shall be remunerated with a monthly stipend of EUR3,500 (US$4,310), and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Mr. Katsaros shall also be entitled to acquire at his discretion 10,000,000 shares of the common stock at a price of $US0.05 for a term of five years commencing January 2, 2018.   The Company recognized stock-based compensation expense allocated to consulting fees of $16,800 during the three months ended March 31, 2018. The unrecognized amount of $320,300 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2021, Mr. Katsaros is entitled to total minimum payments of EUR115,500 (US$141,944).

Schedule of accounts payable and accrued liabilities from related parties

	March 31,			December 31,
	2018			2017
CEO and President (i)	$	306,423		$	413,010
Director (ii)		116,229			95,843
Director (iii)		863			-
VP (iv)		1,848			-
Reclassification to Convertible Debt, Related parties		(422,652	)
	$	2,711		$	508,853

Schedule of advances from related parties

	March 31,			December 31,
	2018			2017
CEO and President (i)	$	283,191		$	287,073
Director (ii)		15,721			54,282
Reclassification to Convertible Debt, Related Parties		(298,912	)
	$	-		$	341,355

XML

Stock Options (Tables)

3 Months Ended

Mar. 31, 2018

Stock Options [Abstract]

Schedule of stock options outstanding

Series A Preferred Stock:

	March 31, 2018				December 31, 2017
	Series A Preferred stock		Weighted Average Exercise Price $		Series A Preferred stock		Weighted Average Exercise Price $
Outstanding at beginning of the year		25,000		0.04		25,000		0.04
Granted		-		-		-		-
Exercised		-		-		-		-
Expired or canceled		-		-		-		-
Outstanding at the period		25,000		0.04		25,000		0.04

Common stock:

	March 31, 2018				December 31, 2017
	Common stock		Weighted Average Exercise Price $		Common stock		Weighted Average Exercise Price $
Outstanding at beginning of the year		28,000,000		0.076		-		-
Granted		10,000,000		0.05		28,000,000		0.076
Exercised		-		-		-		-
Expired or canceled		-		-		-		-
Outstanding at the period		38,000,000		0.070		28,000,000		0.076

Schedule of weighted average fair value of options granted in the Black-Scholes model for stock option grants

Series A Preferred Stock: 

	Options Granted September 30, 2014
Fair value of options granted	1.40 ~ 2.00
Assumptions used:
Expected life (years) (a)		1.00
Risk free interest rate (b)		0.11%
Volatility (c)	117.09 ~ 119.83 %
Dividend yield (d)		0.00

Common stock:

	Options Granted date
Fair value of options granted	0.038 ~ 0.925
Assumptions used:
Expected life (years) (a)	5 ~ 6
Risk free interest rate (b)	1.93% ~ 2.25%
Volatility (c)	175.40% ~ 254.86%
Dividend yield (d)	0.00

XML

Provision for Income Taxes (Tables)

3 Months Ended

Mar. 31, 2018

Provision for Income Taxes [Abstract]

Schedule of provision for income taxes in US, Greece and UK

The provision for income taxes in US consists of the following:

	Three months ended March 31,
	2018			2017
Current operations	$	99,200		$	204,457
Timing differences, Stock based compensation		(96,000	)		(132,226	)
Less, Change in valuation allowance		(3,200	)		(72,231	)
Net refundable amount	$	-		$	-

 The provision for income taxes in Greece consists of the following:

	Three months ended March 31,
	2018			2017
Current operations	$	47,800			$	15,380
Less, Change in valuation allowance		(47,800	)			(15,380	)
Net refundable amount	$	-			$	-

The provision for income taxes in UK consists of the following:

	Three months ended March 31,
	2018			2017
Current operations	$	11,200		$	16,654
Research and development		(16,600	)		(13,113	)
Less, Change in valuation allowance		5,400			(3,541
Net refundable amount	$	-		$	-

Schedule of cumulative tax effect at the expected rates in U.S., in Greece and in U.K. for significant items comprising our net deferred tax amounts

	March 31, 2018									December 31, 2017
	US Expected rate 21%			Greece Expected rate 29%			UK Expected rate 20%			US Expected rate 21%			Greece Expected rate 29%			UK Expected rate 20%
Deferred tax asset attributable to:
Net operating loss carryover		2,891,200			1,391,200			301,680			4,654,100			1,343,400			307,080
Change in effective tax rates		-			-			-			(1,766,100	)		-			-
Less, Valuation allowance		(2,891,200	)		(1,391,200	)		(301,680	)		(2,888,000	)		(1,343,400	)		(307,080	)
Net deferred tax asset		-			-			-			-			-

XML

Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Schedule of segment reporting information

Three months ended March 31, 2018:

	Clinics (UK)		Technology (UK)			All Other (Greece)			Total
Revenue	$	126,890	$	4,890		$	-		$	131,780
Depreciation & amortization	$	2,357	$	11,247		$	5,851		$	19,455
Net (Loss) from operations	$	20,469	$	(76,551	)	$	(637,433	)	$	(693,515	)
Interest expenses	$	-	$	-		$	(614	)	$	(614	)
Assets	$	277,638	$	146,554		$	140,906		$	565,098
Expenditure on long-lived assets	$	-	$	-		$	-		$	-

Three months ended March 31, 2017:

	Clinics (UK)			Technology (UK)			All Other (Greece)			Total
Revenue	$	83,884		$	2,556		$	-		$	86,440
Depreciation & amortization	$	2,231		$	10,771		$	7,906		$	20,908
Loss from operations	$	(23,319	)	$	(58,947	)	$	(652,933	)	$	(735,199	)
Interest expenses	$	(1.040	)	$	-		$	(496	)	$	(1,536	)
Assets	$	60,154		$	158,104		$	95,480		$	313,738
Expenditure on long-lived assets	$	-		$	-		$	-		$	-

XML

Going Concern (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Going Concern (Textual)
Net losses	$ (693,515)	$ (737,645)
Retained deficit	(35,430,148)		$ (34,736,633)
Stockholders' deficit	(818,952)		$ (911,079)
Working capital deficiency	$ 960,149

XML

Control by Principal Stockholder/Officer (Details) - Mr. Leontaritis [Member]	1 Months Ended
	Mar. 30, 2018 shares
Control by Principal Stockholder/Officer (Textual)
Shares of restricted common stock	122,710,562
Sale of outstanding shares of common stock percentage	49.10%
Common stock shares issued	20,000,000
Percentage of issued and outstanding shares	8.00%

XML

Summary of Significant Accounting Policies (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Summary of Significant Accounting Policies [Abstract]
Convertible debt at $0.03 per share	24,052,133
Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options	500,000	500,000
Common stock issuable upon exercise of stock options	38,000,000	28,000,000
Total	62,552,133	28,500,000

XML

Summary of Significant Accounting Policies (Details Textual) - USD ($)

3 Months Ended

Mar. 31, 2018

Mar. 31, 2017

Dec. 31, 2017

Summary of Significant Accounting Policies (Textual)

Research and development costs

$ 83,328

$ 78,066

Foreign currencies translation of financial statements, description

i) assets and liabilities are translated at the closing rate at the date of the balance sheet, or

     1USD=0.81158EUR, 1USD=0.71239GBP (March 31, 2018), and;

1USD=0.8347EUR, 1USD=0.74108GBP (December 31, 2017);

ii) income and expenses are translated at average exchange rates for three months ended March 31, or

         1USD=0.8137EUR, 1USD=0.7189GBP (March 31, 2018), and;

1USD=0.93136EUR, 1USD=0.80731GBP (March 31, 2017);

iii)  all resulting exchange differences are recognized as other comprehensive income, a separate component of equity.

Income tax examination, description

Income tax years for 2014 through 2016 have been remitted timely and remain open to examination by the taxing authorities. The tax return for fiscal 2017 has not yet been filed. The Company has been assessed late filing penalties of $10,000 per year, as well as accrued interest thereon, for each of the late filed returns for the periods from inception to December 31, 2012.

Accrued as taxes payable

$ 80,000

$ 80,000

Series A Preferred Stock Options [Member]

Summary of Significant Accounting Policies (Textual)

Common stock issuable upon conversion of options

25,000

XML

Prepaid Expenses (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Prepaid Expenses [Abstract]
Office lease, including security deposits	$ 41,134	$ 39,582
Travel advances and other expenses	11,808	10,943
Total prepaid expense	$ 52,942	$ 50,525

XML

Property and Equipment (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 387,683	$ 373,146
Less: accumulated depreciation and impairment	(246,486)	(218,117)
Property and equipment, net	141,197	155,029
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	211,628	203,990
Furniture and fixture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	33,967	32,781
Computers and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	35,406	33,144
Vehicle [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	61,608	59,902
Machine and plant [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	9,577	9,206
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$ 35,497	$ 34,123

XML

Property and Equipment (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Property and Equipment (Textual)
Depreciation expense	$ 19,455	$ 20,908
Leasehold improvements [Member] | Minimum [Member]
Property and Equipment (Textual)
Property and equipment useful lifes	3 years
Leasehold improvements [Member] | Maximum [Member]
Property and Equipment (Textual)
Property and equipment useful lifes	10 years
Furniture [Member] | Minimum [Member]
Property and Equipment (Textual)
Property and equipment useful lifes	3 years
Furniture [Member] | Maximum [Member]
Property and Equipment (Textual)
Property and equipment useful lifes	5 years
Computer and equipment [Member]
Property and Equipment (Textual)
Property and equipment useful lifes	3 years
Vehicles [Member]
Property and Equipment (Textual)
Property and equipment useful lifes	5 years
Machine equipment [Member]
Property and Equipment (Textual)
Property and equipment useful lifes	4 years
Lab equipment [Member]
Property and Equipment (Textual)
Property and equipment useful lifes	4 years

XML

Office Lease (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Office Lease [Abstract]
Amount owed for maintenance charges	$ 16,700	$ 16,238
Amount owed for utility charges	17,287	16,807
Balance owing to Lessor amount	$ 33,987	$ 33,045

XML

Office Lease (Details 1) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Operating Leased Assets [Line Items]
Prepaid expenses	$ 41,134	$ 39,582
UK [Member]
Operating Leased Assets [Line Items]
Prepaid expenses	37,437	35,988
Greece [Member]
Operating Leased Assets [Line Items]
Prepaid expenses	$ 3,697	$ 3,594

XML

Office Lease (Details 2)	Mar. 31, 2018 USD ($)
United Kingdom [Member]
Operating Leased Assets [Line Items]
2018	$ 33,340
2019	53,810
2020	9,360
Total	96,510
Greece [Member]
Operating Leased Assets [Line Items]
2018	17,200
2019	23,000
2020	3,800
Total	$ 44,000

XML

Office Lease (Details Textual)									3 Months Ended
	Sep. 01, 2015 USD ($)	Sep. 01, 2015 EUR (€)	Mar. 02, 2015 USD ($) ft²	Mar. 02, 2015 GBP (£)	Dec. 29, 2014 USD ($)	Dec. 29, 2014 EUR (€)	Feb. 03, 2014 USD ($)	Feb. 03, 2014 EUR (€)	Mar. 31, 2018 USD ($)	Mar. 31, 2018 EUR (€)	Mar. 31, 2017 USD ($)	Mar. 31, 2018 GBP (£)	Mar. 02, 2015 GBP (£) ft²	Dec. 29, 2014 EUR (€)	Feb. 03, 2014 EUR (€)
Office Lease (Textual)
Rental fee									$ 28,586		$ 18,704
Security deposits									28,075			£ 20,000
Office in Greece [Member]
Office Lease (Textual)
Lease agreement term, description							The Company leased office space in Paleo Faliro, Greece on a three-year lease, commencing on March 1, 2014 and ending on February 28, 2017.	The Company leased office space in Paleo Faliro, Greece on a three-year lease, commencing on March 1, 2014 and ending on February 28, 2017.
Rental fee							$ 1,900	€ 1,554
Lease agreement payment							25,010	€ 18,540
Lease deposit							$ 4,047								€ 3,000
Rental fee term							10 months	10 months
Prepaid deposit									3,697	€ 3,000
Lease fees, during first year									17,200
Lease fees, during second anniversary									23,000
Lease fees, during third anniversary									$ 3,800
Simple annual rate percentage points							2.00%	2.00%
Lease expired and renewed									Renewed effective June 13, 2017 for a term of 3 years terminating on February 28, 2020 at a rate of $1,960 (EUR 1,592) plus a fee of 3.6	Renewed effective June 13, 2017 for a term of 3 years terminating on February 28, 2020 at a rate of $1,960 (EUR 1,592) plus a fee of 3.6
Lease in UK [Member]
Office Lease (Textual)
Prepaid deposit			$ 25,940	£ 20,000
Area of Land | ft²			5,300										5,300
Lease fees, during first year									$ 33,340
Lease fees, during second anniversary									53,810
Lease fees, during third anniversary									$ 9,360
Lease in UK [Member] | VAT [Member]
Office Lease (Textual)
Lease fees, during first year			$ 28,000										£ 20,000
Lease fees, during second anniversary			56,000										40,000
Lease fees, during third anniversary			56,000										40,000
Lease fees, during fourth anniversary			42,000										30,000
Lease fees, during fifth anniversary			$ 56,000										£ 40,000
Clinic in Greece [Member]
Office Lease (Textual)
Lease agreement term, description					The Company leased office space at Peania Region of Attica in Greece on a ten-year lease, commencing on January 1, 2015 and ending on October 5, 2024.	The Company leased office space at Peania Region of Attica in Greece on a ten-year lease, commencing on January 1, 2015 and ending on October 5, 2024.
Rental fee	$ 3,500	€ 3,116			$ 6,996	€ 6,233
Lease deposit					13,991									€ 12,465
Operating cost					$ 1,120	€ 997

XML

Loans (Details)			3 Months Ended
	Jan. 05, 2017 USD ($)	Jan. 05, 2017 EUR (€)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Loans (Textual)
Loans from third party borrow			$ 359,381
HCi Viocare Clinics Hellas S.A. [Member]
Loans (Textual)
Loans from third party borrow	$ 49,287	€ 40,000
Loan payable, interest rate	5.00%	5.00%
Loans payable, description	One year from the date of the agreement.	One year from the date of the agreement.
Loan payable			52,325	$ 50,276
Accrued interest expenses			$ 614

XML

Commitments (Details)								1 Months Ended
	Dec. 12, 2017 USD ($) $ / shares shares	Dec. 12, 2017 EUR (€) shares	Oct. 09, 2017 USD ($) $ / shares shares	Sep. 01, 2017 USD ($) $ / shares shares	Jan. 03, 2017 EUR (€)	Mar. 01, 2016 shares	Apr. 16, 2014	Mar. 27, 2018 USD ($) $ / shares shares	Feb. 26, 2018 USD ($) $ / shares shares	Feb. 26, 2018 EUR (€) shares	Aug. 28, 2017 shares	Jul. 10, 2017 USD ($) $ / shares shares	Mar. 17, 2017 USD ($) shares	Jul. 19, 2017
Commitments (Textual)
Percentage of success fee														90.00%
Sergios Katsaros [Member]
Commitments (Textual)
Issuance of common shares for the services						300,000							1,000,000
Granted shares											1,000,000
Fair market value on grant date | $													$ 170,000
Consulting Agreement [Member] | Kapatos [Member]
Commitments (Textual)
Agreement, description							The Company entered into a Consulting Agreement with Christos Kapatos whereby he will provide his services as Chief Technical Officer for the Company and the Company's wholly-owned subsidiaries. The contract has a term of one year, renewable for such further term as may be mutually agreed between the parties. In the case that a research and development project is initiated and completed during the term of the agreement, Kapatos shall receive one million four hundred thousand (1,400,000) shares of the Company's common stock for each research project completed with a valuation less than twenty million dollars ($20,000,000 USD), three million five hundred thousand (3,500,000) shares of the Company's common stock for each research project completed with a valuation equal or greater than twenty million US dollars ($20,000,000 USD). Details of compensation under the terms of the consulting agreement are included in Note 10(ii).
Consulting Agreement [Member] | JAMB Group LLC [Member]
Commitments (Textual)
Agreement, description												The Company entered into a business consulting agreement (the "Consulting Agreement") with JAMB Group LLC. ("Consultant") for services to commence July 15, 2017 and to continue for a period of twelve (12) months thereafter.
Issuance of common shares for the services												500,000
Granted shares												500,000
Fair market value on grant date | $												$ 79,950
Fair market price on the date of grant | $ / shares												$ 0.1599
Consulting Agreement [Member] | Mr. Stefanos Batzakis [Member]
Commitments (Textual)
Agreement, description				The Company entered into a one-year consulting agreement (the "Agreement") with Mr Stefanos Batzakis. As per terms of said Agreement Batzakis will provide services to the Company as IT Solutions Manager, for a term of one (1) year and receive compensation in the form of stock, namely five hundred thousand (500,000) common shares, which were issued upon signing of this Agreement.
Issuance of common shares for the services				500,000
Granted shares				500,000
Fair market value on grant date | $				$ 40,000
Fair market price on the date of grant | $ / shares				$ 0.08
Consulting Agreement [Member] | Dr. Ioannis Doupis [Member]
Commitments (Textual)
Agreement, description			The Company appointed Dr. Ioannis Doupis, to the Advisory Board of the Company originally formed on April 15, 2014 and Concurrently entered into an advisory board agreement. Compensation shall be the grant of a total of 500,000 shares of the Company's common stock valued at the fair market price on the date of grant of $0.07 per share. The advisory board appointment is for a term of one year.
Issuance of common shares for the services			500,000
Granted shares			500,000
Fair market value on grant date | $			$ 35,000
Fair market price on the date of grant | $ / shares			$ 0.07
Consulting Agreement [Member] | Ms. Paraskevi Pilarinou [Member]
Commitments (Textual)
Agreement, description	The Company entered into a consulting agreement (the "Agreement") with an Ms. Paraskevi Pilarinou (the "Consultant"). Under the terms and conditions of the Agreement the Consultant shall be employed in the position of Financial Controller of the Company. The Agreement has a three-year term starting on January 2, 2018 and ending on January 1, 2021 and the Consultant shall be remunerated with a monthly fee of EUR2,000 (IUSD$2,460) and was issued 2,000,000 shares of the Company's common stock. The 2,000,000 shares were issued as compensation as of the date of the agreement and were valued at $0.05 per share or $100,000, the fair market value on the date of issuance in the year ended December 31, 2017.	The Company entered into a consulting agreement (the "Agreement") with an Ms. Paraskevi Pilarinou (the "Consultant"). Under the terms and conditions of the Agreement the Consultant shall be employed in the position of Financial Controller of the Company. The Agreement has a three-year term starting on January 2, 2018 and ending on January 1, 2021 and the Consultant shall be remunerated with a monthly fee of EUR2,000 (IUSD$2,460) and was issued 2,000,000 shares of the Company's common stock. The 2,000,000 shares were issued as compensation as of the date of the agreement and were valued at $0.05 per share or $100,000, the fair market value on the date of issuance in the year ended December 31, 2017.
Issuance of common shares for the services	2,000,000	2,000,000
Fair market value on grant date | $	$ 100,000
Fair market price on the date of grant | $ / shares	$ 0.05
Consultant remuneration monthly fee	$ 2,460	€ 2,000
Shares issued compensation	2,000,000	2,000,000
Consulting Agreement [Member] | Charalampos Sgardelis [Member]
Commitments (Textual)
Compensation receivables | €					€ 2,000					€ 3,000
Agreement, description					The Company entered into a one-year consulting agreement (the "Agreement") with Mr. Charalampos Sgardelis ("Sgardelis"). Under the terms of the Agreement, Sgardelis provides services to the Company as Business Development Manager, for a term of one (1) year and receives compensation of Two Thousand Euros (2,000 ) per month.				The Company approved a three (3) year extension to the Agreement (the "Addendum") between the Company and Sgardelis. Under the terms and conditions of the Addendum, Sgardelis is entitled to receive compensation of Three Thousand Euros (3,000 ) per month and shall be awarded five million (5,000,000) common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $0.049 per share for total consideration of $245,000.	The Company approved a three (3) year extension to the Agreement (the "Addendum") between the Company and Sgardelis. Under the terms and conditions of the Addendum, Sgardelis is entitled to receive compensation of Three Thousand Euros (3,000 ) per month and shall be awarded five million (5,000,000) common shares upon execution of the Addendum. The shares were valued at fair market value on the date of issuance or $0.049 per share for total consideration of $245,000.
Fair market price on the date of grant | $ / shares									$ 0.049
Shares issued compensation									5,000,000	5,000,000
Total consideration | $									$ 245,000
Consulting Agreement [Member] | Ravi Vaidyanathan [Member]
Commitments (Textual)
Agreement, description								The Company entered into a one-year advisory agreement (the "Agreement") with an Mr. Ravi Vaidyanathan (the "Advisor"). Under the terms and conditions of the Agreement, the Advisor is appointed to the Company's Scientific Advisory Board and is entitled to remuneration for the provision of services in the form of 500,000 shares of the common stock to be issued upon signing of the Agreement. Further, the Advisor shall be granted additional 250,000 shares of the common stock to be issued after a time-period of six (6) months from the signing of the Agreement.
Issuance of common shares for the services								500,000
Fair market price on the date of grant | $ / shares								$ 0.055
Total consideration | $								$ 27,500

XML

Related Party Transactions (Details) - USD ($)		3 Months Ended
		Mar. 31, 2018	Mar. 31, 2017
Schedule of services provided from related parties
Professional fees		$ 19,436	$ 239,139
Services provided from related parties, Total		255,461	409,444
CEO and President [Member]
Schedule of services provided from related parties
Consulting fees	[1]	38,867	30,000
Stock options granted	[1]	122,543	122,543
Director [Member]
Schedule of services provided from related parties
Consulting fees	[2]	15,361	10,655
Professional fees	[3]	3,687	3,196
Stock options granted	[2]	45,300
Stock award granted	[3]		172,000
VP [Member]
Schedule of services provided from related parties
Consulting fees	[4]	12,903	6,393
Stock options granted	[4]	16,800
Stock award granted	[4]		$ 187,200

[1] On September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016. Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract. In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR$10,000 per month. Further, Mr. Leontaritis is entitled to acquire at his discretion 3,000,000 shares of the common stock at a price of $0.30 per share for a term of five (5) years. The Company recognized stock-based compensation expense allocated to consulting fees of $122,543 during the three months ended March 31, 2018 and 2017. The unrecognized amount of $1,838,151 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2019, Mr. Leontaritis is entitled to total minimum payments of EUR$210,000 (US$258,080).

[2] On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$49,290 ( 40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company Euros 40,000 for services rendered in each fiscal year respectively. On December 12, 2017, the Company approved the issuance of 18,500,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant. The 18,500,000 shares have been valued at $925,000, or $0.05 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$61,610) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 25,000,000 shares of the common stock at a price of $US0.05 for a term of six years. The Company recognized stock-based compensation expense allocated to consulting fees of $45,300 during the three months ended March 31, 2018. The unrecognized amount of $1,030,200 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2023, Dr. Kapatos is entitled to total minimum payments of EUR287,500 (US$353,324).

[3] On September 10, 2013, the Board of Directors of the Company elected Nikolaos Kardaras as Secretary and a director of the Company. During each of fiscal 2017 and fiscal 2016, Mr. Kardaras invoiced the Company EUR12,000 for services rendered in his capacity as a director which amount totaled US$13,500 and $13,300 respectively. On March 3, 2017, the Company approved the issuance of 1,000,000 common shares for the services provided by Mr. Nikolaos Kardaras in the form of a stock award which vested as of the date of grant. 1,000,000 shares have been valued at $172,000, the fair market value of $0.172 per share on issue date, which amount has been expensed as stock based compensation.

[4] On September 1, 2015, the Board of Directors of the Company approved a consulting agreement with Sergios Katsaros and appointed Mr. Katsaros Vice President. Under the terms of the consulting agreement, Mr. Katsaros will work directly with the Company's President and CEO in order to create and implement the Company's strategic plan and assist in securing additional financing to meet the needs of the Company's business plan and corporate objectives. The initial term of the contract is six months and Mr. Katsaros will receive compensation of USD$2,460 ( 2,000) per month. On March 1, 2016, the Company approved a one-year extension to the consulting agreement and the Company approved the grant of a stock award of 300,000 common shares as compensation for the services provided by Vice President, Sergios Katsaros. The award vests in three equal instalments of 100,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. During fiscal 2016 a total of $169,000 in respect of 200,000 vested shares was recorded as stock based compensation. On March 1, 2017, the final instalment of 100,000 shares were issued in accordance with the terms of the award valued at $17,200, the fair market value on grant date, which amount has been expensed as stock-based compensation in 2017. On March 17, 2017, the Company approved the issuance of a further 1,000,000 common shares for the services provided by Mr. Katsaros, in the form of a stock award which vested as of the date of grant. 1,000,000 shares have been valued at $170,000, the fair market value of $0.17 per share on grant date, which amount has been expensed as stock-based compensation. On December 12, 2017 the Company approved a three-year extension to the consulting agreement between the Company and Mr. Katsaros effective as of January 2, 2018. The revision to the Agreement has a term of three years, being effective as of January 2, 2018, and ending on January 1, 2021, renewable for such further term as may be mutually agreed between the parties. Mr. Katsaros shall be remunerated with a monthly stipend of EUR3,500 (US$4,310), and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Mr. Katsaros shall also be entitled to acquire at his discretion 10,000,000 shares of the common stock at a price of $US0.05 for a term of five years commencing January 2, 2018. The Company recognized stock-based compensation expense allocated to consulting fees of $16,800 during the three months ended March 31, 2018. The unrecognized amount of $320,300 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2021, Mr. Katsaros is entitled to total minimum payments of EUR115,500 (US$141,944).

XML

Related Party Transactions (Details 1) - USD ($)		Mar. 31, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities from related parties		$ 2,711	$ 508,853
CEO and President [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities from related parties	[1]	306,423	413,010
Director [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities from related parties	[2]	116,229	95,843
Director Two [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities from related parties	[3]	863
VP [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities from related parties	[4]	1,848
Reclassification to Convertible Debt, Related parties [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities from related parties		$ (422,652)

[1] On September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016. Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract. In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR$10,000 per month. Further, Mr. Leontaritis is entitled to acquire at his discretion 3,000,000 shares of the common stock at a price of $0.30 per share for a term of five (5) years. The Company recognized stock-based compensation expense allocated to consulting fees of $122,543 during the three months ended March 31, 2018 and 2017. The unrecognized amount of $1,838,151 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2019, Mr. Leontaritis is entitled to total minimum payments of EUR$210,000 (US$258,080).

[2] On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$49,290 ( 40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company Euros 40,000 for services rendered in each fiscal year respectively. On December 12, 2017, the Company approved the issuance of 18,500,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant. The 18,500,000 shares have been valued at $925,000, or $0.05 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$61,610) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 25,000,000 shares of the common stock at a price of $US0.05 for a term of six years. The Company recognized stock-based compensation expense allocated to consulting fees of $45,300 during the three months ended March 31, 2018. The unrecognized amount of $1,030,200 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2023, Dr. Kapatos is entitled to total minimum payments of EUR287,500 (US$353,324).

[3] On September 10, 2013, the Board of Directors of the Company elected Nikolaos Kardaras as Secretary and a director of the Company. During each of fiscal 2017 and fiscal 2016, Mr. Kardaras invoiced the Company EUR12,000 for services rendered in his capacity as a director which amount totaled US$13,500 and $13,300 respectively. On March 3, 2017, the Company approved the issuance of 1,000,000 common shares for the services provided by Mr. Nikolaos Kardaras in the form of a stock award which vested as of the date of grant. 1,000,000 shares have been valued at $172,000, the fair market value of $0.172 per share on issue date, which amount has been expensed as stock based compensation.

[4] On September 1, 2015, the Board of Directors of the Company approved a consulting agreement with Sergios Katsaros and appointed Mr. Katsaros Vice President. Under the terms of the consulting agreement, Mr. Katsaros will work directly with the Company's President and CEO in order to create and implement the Company's strategic plan and assist in securing additional financing to meet the needs of the Company's business plan and corporate objectives. The initial term of the contract is six months and Mr. Katsaros will receive compensation of USD$2,460 ( 2,000) per month. On March 1, 2016, the Company approved a one-year extension to the consulting agreement and the Company approved the grant of a stock award of 300,000 common shares as compensation for the services provided by Vice President, Sergios Katsaros. The award vests in three equal instalments of 100,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. During fiscal 2016 a total of $169,000 in respect of 200,000 vested shares was recorded as stock based compensation. On March 1, 2017, the final instalment of 100,000 shares were issued in accordance with the terms of the award valued at $17,200, the fair market value on grant date, which amount has been expensed as stock-based compensation in 2017. On March 17, 2017, the Company approved the issuance of a further 1,000,000 common shares for the services provided by Mr. Katsaros, in the form of a stock award which vested as of the date of grant. 1,000,000 shares have been valued at $170,000, the fair market value of $0.17 per share on grant date, which amount has been expensed as stock-based compensation. On December 12, 2017 the Company approved a three-year extension to the consulting agreement between the Company and Mr. Katsaros effective as of January 2, 2018. The revision to the Agreement has a term of three years, being effective as of January 2, 2018, and ending on January 1, 2021, renewable for such further term as may be mutually agreed between the parties. Mr. Katsaros shall be remunerated with a monthly stipend of EUR3,500 (US$4,310), and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Mr. Katsaros shall also be entitled to acquire at his discretion 10,000,000 shares of the common stock at a price of $US0.05 for a term of five years commencing January 2, 2018. The Company recognized stock-based compensation expense allocated to consulting fees of $16,800 during the three months ended March 31, 2018. The unrecognized amount of $320,300 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2021, Mr. Katsaros is entitled to total minimum payments of EUR115,500 (US$141,944).

XML

Related Party Transactions (Details 2) - USD ($)		Mar. 31, 2018	Dec. 31, 2017
Schedule of advances from related parties
Advances from related parties			$ 341,355
CEO and President [Member]
Schedule of advances from related parties
Advances from related parties	[1]	283,191	287,073
Director [Member]
Schedule of advances from related parties
Advances from related parties	[2]	15,721	54,282
Reclassification to Convertible Debt, Related parties [Member]
Schedule of advances from related parties
Advances from related parties		$ (298,912,000)

[1] On September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016. Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract. In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR$10,000 per month. Further, Mr. Leontaritis is entitled to acquire at his discretion 3,000,000 shares of the common stock at a price of $0.30 per share for a term of five (5) years. The Company recognized stock-based compensation expense allocated to consulting fees of $122,543 during the three months ended March 31, 2018 and 2017. The unrecognized amount of $1,838,151 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2019, Mr. Leontaritis is entitled to total minimum payments of EUR$210,000 (US$258,080).

[2] On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$49,290 ( 40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company Euros 40,000 for services rendered in each fiscal year respectively. On December 12, 2017, the Company approved the issuance of 18,500,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant. The 18,500,000 shares have been valued at $925,000, or $0.05 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$61,610) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 25,000,000 shares of the common stock at a price of $US0.05 for a term of six years. The Company recognized stock-based compensation expense allocated to consulting fees of $45,300 during the three months ended March 31, 2018. The unrecognized amount of $1,030,200 will be expensed in future periods. Over the remaining term of his contract which expires in fiscal 2023, Dr. Kapatos is entitled to total minimum payments of EUR287,500 (US$353,324).

XML

Related Party Transactions (Details Textual)											1 Months Ended				3 Months Ended		12 Months Ended
	Dec. 12, 2017 USD ($) $ / shares shares	Dec. 12, 2017 EUR (€) shares	Mar. 03, 2017 USD ($) $ / shares shares	Mar. 01, 2017 USD ($) shares	Mar. 01, 2016 shares	Sep. 01, 2015 USD ($)	Sep. 01, 2015 EUR (€)	Apr. 16, 2014 USD ($)	Apr. 16, 2014 EUR (€)	Jan. 15, 2014	Feb. 15, 2018	Aug. 28, 2017 shares	Mar. 17, 2017 USD ($) $ / shares shares	May 28, 2015 shares	Mar. 31, 2018 USD ($) $ / shares shares	Mar. 31, 2017 USD ($)	Dec. 31, 2017 USD ($) shares	Dec. 31, 2017 EUR (€) shares	Dec. 31, 2016 USD ($)	Dec. 31, 2016 EUR (€)	Mar. 31, 2018 EUR (€)
Related Party Transactions (Textual)
Related party payments, description											Company's common stock at a price equal or greater to $0.03 per share. On the date of the agreement the fair market value of the Company's common stock as traded on OTCMarkets was $0.0403 per share.
Issuance of common shares as compensation						$ 2,460	€ 2,000
Invoiced for services rendered | €																		€ 40,000		€ 40,000
Issuance of common stock, Value | $			$ 172,000
Percentage annual compensation	100.00%	100.00%
Granted shares | shares			1,000,000
Fair market value price | $ / shares			$ 0.172
Vested values | $																			169,000
Monthly stipend	$ 4,310	€ 3,500
Convertible debt, related parties | $															$ 721,564
Convertible restricted common stock | shares															24,052,133
Mr. Leontaritis [Member]
Related Party Transactions (Textual)
Term of acquire discretion common stock															5 years
Acquire discretion common stock shares | shares															3,000,000
Common stock price per share | $ / shares															$ 0.30
Related party payments, description										Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract. In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR$10,000 per month.
Description of payment terms															Over the remaining term of his contract which expires in fiscal 2019, Mr. Leontaritis is entitled to total minimum payments of EUR$210,000 (US$258,080).
Total minimum payments															$ 258,080						€ 210,000
Consulting fees | $															122,543	$ 122,543
Unrecognized amount | $															$ 1,838,151
Christos Kapatos [Member]
Related Party Transactions (Textual)
Common stock price per share | $ / shares	$ 0.05
Description of payment terms															Over the remaining term of his contract which expires in fiscal 2023.
Issuance of common shares for the services | shares			1,000,000
Fair market value on grant date | $			$ 172,000
Total minimum payments															$ 353,324						287,500
Consulting fees | $															45,300
Unrecognized amount | $															$ 1,030,200
Compensation expenses	$ 61,610	€ 50,000						$ 49,290	€ 40,000
Issuance of common stock | shares	18,500,000	18,500,000
Issuance of common stock, Value | $	$ 925,000
Percentage annual compensation	100.00%	100.00%
Director acquire discretion common stock | shares	25,000,000	25,000,000
Director acquire discretion common stock per share | $ / shares	$ 0.05
Vice President [Member]
Related Party Transactions (Textual)
Issuance of common shares for the services | shares					300,000								1,000,000
Granted shares | shares												1,000,000
Fair market value on grant date | $													$ 170,000
Issuance of common stock | shares				100,000
Vice President [Member] | Final installments [Member]
Related Party Transactions (Textual)
Granted shares | shares					100,000
Vice President [Member] | Installments [Member]
Related Party Transactions (Textual)
Granted shares | shares				100,000
Fair market value on grant date | $				$ 17,200
Nikolaos Kardaras [Member]
Related Party Transactions (Textual)
Issuance of common shares for the services | shares			1,000,000											700,000
Invoiced for services rendered																	$ 13,500	€ 12,000	$ 13,300	€ 12,000
Nikolaos Kardaras [Member] | Installments [Member]
Related Party Transactions (Textual)
Description of payment terms															Over the remaining term of his contract which expires in fiscal 2021.
Total minimum payments															$ 141,944						€ 115,500
Consulting fees | $															16,800
Unrecognized amount | $															$ 320,300
Katsaros [Member]
Related Party Transactions (Textual)
Common stock price per share | $ / shares													$ 0.17
Issuance of common stock | shares	10,000,000	10,000,000

XML

Capital Stock (Details) - USD ($)		3 Months Ended	12 Months Ended
	Jan. 13, 2014	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Capital Stock (Textual)
Preferred Stock, shares authorized		5,000,000	5,000,000
Preferred stock, par value		$ 0.0001	$ 0.0001
Common Stock, shares authorized		700,000,000	700,000,000
Common stock, par value		$ 0.0001	$ 0.0001
Shares issuance for services provided				$ 715,164
Employees, board members and consultants [Member]
Capital Stock (Textual)
Shares issuance for services provided		$ 272,500
Shares issuance for services provided, shares		5,500,000
Private placements [Member]
Capital Stock (Textual)
Total cash proceeds of common stock		$ 359,381
Number of shares issued		12,148,168
Series A Preferred Stock [Member]
Capital Stock (Textual)
Preferred stock, par value		$ 0.04
Stock options granted shares		25,000
Vested stock options, shares		25,000
Vested stock options, period		5 years
Common stock shares issued	5,000,000
Description of preferred stock voting rights	The holders of Series A Preferred Stock will be entitled to a preference over all of the shares of the Company's common stock. Holders of Series A Preferred Stock shall have 50 votes per share of Series A Preferred Stock held by them and shall be entitled to notice of any stockholders' meeting and to vote as a single class upon any matter submitted to the stockholders for a vote. Each share of Series A Preferred Stock is convertible into 20 shares of our common stock at any time at the holder's option. Shares of Series A Preferred Stock shall not be entitled to any dividends.

XML

Stock Options (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Series A Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of the year	25,000	25,000
Granted
Exercised
Expired or canceled
Outstanding at the period	25,000	25,000
Weighted Average Exercise Price, Outstanding at beginning of the year	$ 0.04	$ 0.04
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired or canceled
Weighted Average Exercise Price, Outstanding at the period	$ 0.04	$ 0.04
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of the year	28,000,000
Granted	10,000,000	28,000,000
Exercised
Expired or canceled
Outstanding at the period	38,000,000	28,000,000
Weighted Average Exercise Price, Outstanding at beginning of the year	$ 0.076
Weighted Average Exercise Price, Granted	0.05	0.076
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired or canceled
Weighted Average Exercise Price, Outstanding at the period	$ 0.070	$ 0.076

XML

Stock Options (Details 1)	1 Months Ended
	Sep. 30, 2014 $ / shares
Series A Preferred Stock [Member]
Assumptions used:
Expected life (years) (a)	1 year
Risk free interest rate (b)	0.11%
Dividend yield (d)	0.00%
Series A Preferred Stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of options granted	$ 1.40
Assumptions used:
Volatility (c)	117.09%
Series A Preferred Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of options granted	$ 2.00
Assumptions used:
Volatility (c)	119.83%
Common stock [Member]
Assumptions used:
Dividend yield (d)	0.00%
Common stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of options granted	$ 0.038
Assumptions used:
Expected life (years) (a)	5 years
Risk free interest rate (b)	1.93%
Volatility (c)	175.40%
Common stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of options granted	$ 0.925
Assumptions used:
Expected life (years) (a)	6 years
Risk free interest rate (b)	2.25%
Volatility (c)	254.86%

XML

Stock Options (Details Textual) - USD ($)				1 Months Ended	3 Months Ended		12 Months Ended
	Dec. 12, 2017	Apr. 30, 2014	Jan. 13, 2014	Jun. 30, 2014	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Stock Options (Textual)
Stock-based compensation expense allocated to consulting fees					$ 184,643	$ 122,543
Unrecognized amount of stock options					$ 3,188,651
Mr.Leontaritis [Member]
Stock Options (Textual)
Expected life term					5 years
Acquire discretion common stock shares					3,000,000
Acquisition of stock price per share					$ 0.30
Agreement term					On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019.
Common Stock [Member]
Stock Options (Textual)
Granted shares					10,000,000		28,000,000
Expected life term					5 years 6 months 18 days
Common Stock [Member] | Dr. Christos Kapatos [Member]
Stock Options (Textual)
Common stock average remaining life	6 years
Acquire discretion common stock shares	25,000,000
Acquisition of stock price per share	$ 0.05
Common Stock [Member] | Katsaros [Member]
Stock Options (Textual)
Share price					$ 0.05
Expected life term					5 years
Acquire discretion common stock shares					10,000,000
Series A Preferred Stock [Member]
Stock Options (Textual)
Granted shares
Description of preferred stock voting rights			The holders of Series A Preferred Stock will be entitled to a preference over all of the shares of the Company's common stock. Holders of Series A Preferred Stock shall have 50 votes per share of Series A Preferred Stock held by them and shall be entitled to notice of any stockholders' meeting and to vote as a single class upon any matter submitted to the stockholders for a vote. Each share of Series A Preferred Stock is convertible into 20 shares of our common stock at any time at the holder's option. Shares of Series A Preferred Stock shall not be entitled to any dividends.
Expected life term					1 year 26 days
Series A Preferred Stock [Member] | Stock Options [Member]
Stock Options (Textual)
Stock options granted		25,000		25,000
Granted shares					5,000
Description of preferred stock voting rights					The Series A Preferred shares are convertible on the basis of 20 shares of common stock for each one share held and have voting rights of 50 votes per share of Series A Preferred stock held at any meetings of the stockholders.
Share price					$ 0.04
Expected life term					5 years

XML

Provision for Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
US [Member]
Schedule of provision for income taxes in US, Greece and UK
Current operations	$ 99,200	$ 204,457
Timing differences, Stock based compensation	(96,000)	(132,226)
Less, Change in valuation allowance	(3,200)	(72,231)
Net refundable amount
Greece [Member]
Schedule of provision for income taxes in US, Greece and UK
Current operations	47,800	15,380
Less, Change in valuation allowance	(47,800)	(15,380)
Net refundable amount
UK [Member]
Schedule of provision for income taxes in US, Greece and UK
Current operations	11,200	16,654
Research and development	(16,600)	(13,113)
Less, Change in valuation allowance	5,400	(3,541)
Net refundable amount

XML

Provision for Income Taxes (Details 1) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
US Expected rate 21% [Member]
Deferred tax asset attributable to:
Net operating loss carryover	$ 2,891,200	$ 4,654,100
Change in effective tax rates		(1,766,100)
Less, Valuation allowance	(2,891,200)	(2,888,000)
Net deferred tax asset
Greece Expected rate 29% [Member]
Deferred tax asset attributable to:
Net operating loss carryover	1,391,200	1,343,400
Change in effective tax rates
Less, Valuation allowance	(1,391,200)	(1,343,400)
Net deferred tax asset
UK Expected rate 20% [Member]
Deferred tax asset attributable to:
Net operating loss carryover	301,680	307,080
Change in effective tax rates
Less, Valuation allowance	(301,680)	(307,080)
Net deferred tax asset

XML

Provision for Income Taxes (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Provision for Income Taxes (Textual)
Income tax rate		21.00%
Operating loss carryforwards, description	The Internal Revenue Code allows net operating losses (NOL's) to be carried forward and applied against future profits for a period of twenty years. The Greece Tax Code permits such carryforwards for a period of five years.
Corporate income tax rate	21.00%
Late filing penalties		$ 80,000
United Kingdom [Member]
Provision for Income Taxes (Textual)
Net operating losses carryforwards	$ 301,680	$ 307,080
Income tax rate	20.00%
Expected income tax rate	20.00%	20.00%
Greece [Member]
Provision for Income Taxes (Textual)
Net operating losses carryforwards	$ 1,391,200	$ 1,343,400
Expected income tax rate	29.00%	29.00%
Net income earnings, description	The Company's operations in Greece have no tax free income threshold and are subject to taxation at a rate of 29% applied to all net income earned after $1 Euro.
US [Member]
Provision for Income Taxes (Textual)
Net operating losses carryforwards	$ 2,891,200	$ 2,888,000
Expected income tax rate	21.00%	21.00%

XML

Segment Reporting (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Segment Reporting Information [Line Items]
Revenue	$ 131,780	$ 86,440
Depreciation & amortization	19,455	20,908
Net (Loss) from operations	(694,726)	(735,199)
Interest expenses	(614)	(1,536)
Assets	565,098		$ 649,831
Expenditure on long-lived assets
Clinics [Member] | UK [Member]
Segment Reporting Information [Line Items]
Revenue	126,890	83,884
Depreciation & amortization	2,357	2,231
Net (Loss) from operations	20,469	(23,319)
Interest expenses		(1,040)
Assets	277,638	60,154
Expenditure on long-lived assets
Technology [Member] | UK [Member]
Segment Reporting Information [Line Items]
Revenue	4,890	2,556
Depreciation & amortization	11,247	10,771
Net (Loss) from operations	(76,551)	(58,947)
Interest expenses
Assets	146,554	158,104
Expenditure on long-lived assets
All Other [Member] | Greece [Member]
Segment Reporting Information [Line Items]
Revenue
Depreciation & amortization	5,851	7,906
Net (Loss) from operations	(637,433)	(652,933)
Interest expenses	(614)	(496)
Assets	140,906	95,480
Expenditure on long-lived assets

XML

Segment Reporting (Details Textual)	3 Months Ended
	Mar. 31, 2018 Segement
Segment Reporting (Textual)
Number of reportable segments	2

XML

Subsequent Events (Details) - USD ($)				1 Months Ended		3 Months Ended	12 Months Ended
	Jun. 11, 2018	Jun. 07, 2018	May 03, 2018	May 24, 2018	Mar. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Total proceeds of restricted common stock amount
Private Placement Subscription Agreements [Member]
Subsequent Event [Line Items]
Total cash proceeds of common stock						$ 359,381
Common stock at a purchase share						12,148,168
Mr. Leontaritis [Member]
Subsequent Event [Line Items]
Shares of restricted common stock					122,710,562
Common stock price						$ 0.03
Unpaid salary amount						$ 589,614
Common stock shares issued					20,000,000
Total cash proceeds of common stock						$ 100,000
Common stock at a purchase share						3,333,333
Subsequent Events [Member] | Mr. Nikolaos Gemelos [Member]
Subsequent Event [Line Items]
Shares of restricted common stock			100,000
Total consideration			$ 6,700
Fair market value per share			$ 0.067
Subsequent Events [Member] | Mr. Dritsoulas [Member]
Subsequent Event [Line Items]
Shares of restricted common stock		50,000
Advisory board, term		6 months
Subsequent Events [Member] | Rafina Innovations Inc [Member]
Subsequent Event [Line Items]
Reverse stock split				A reverse share split on the basis 20 for 1.
Common stock authorized capital description				Upon effect of the reverse split, our authorized capital will decrease from 700,000,000 shares of common stock to 35,000,000 shares of common stock and correspondingly, our current issued and outstanding shares of common stock will decrease from 259,762,025 to approximately 12,988,101 shares of common stock, all with a par value of $0.0001.
Subsequent Events [Member] | Mr. Constantinos Zertalis [Member] | Private Placement Subscription Agreements [Member]
Subsequent Event [Line Items]
Shares of restricted common stock	122,710,562
Total cash proceeds of common stock	$ 14,724
Common stock at a purchase share	294,840
Total proceeds of restricted common stock amount	$ 986,815
Common stock purchase price	$ 0.05